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IN THE UTAH COURT OF APPEALS 
C&Y CORP., a Utah corporation, 
ROBERT A. CONDIE, an individual, 
JAMES YARTER, an individual, 
Plaintiffs and Appellants, 
vs. 
GENERAL BIOMETRICS, INC., a 
Delaware corporation, VENTANA 
GROWTH FUND, a California limi-
ted partnership, and THOMAS 
GEPHART, an individual, 
Defendants and Appellees. 
BRIEF OF APPELLEES VENTANA 
GROWTH FUND AND THOMAS GEPHART 
Case No. 940340-CA 
Argument Priority 15 
APPEAL FROM JUDGMENT ENTERED BY THE SECOND JUDICIAL DISTRICT 
COURT, DAVIS COUNTY, STATE OF UTAH, THE HONORABLE JON MEMMOTT 
Pursuant to Rule 24 (i) of the Utah Rules of Appellate 
Procedure,1 defendants Ventana Growth Fund ("Ventana") and Thomas 
Gephart ("Gephart") hereby adopt and incorporate by reference all 
sections of the brief of Defendant General Biometrics, Inc.'s 
("GenBio") Brief filed on or about August 9, 1994, except for 
Section V dealing with GenBio's counterclaim for breach of 
fiduciary duty, which does not relate to Ventana and Gephart. For 
reasons of judicial economy, Ventana and Gephart have attempted not 
to duplicate the same well-reasoned arguments made in GenBio's 
LAddendum E, 
Brief. Instead, Ventana and Gephart will provide herein additional 
and supplementary arguments to those contained in GenBio's Brief. 
JURISDICTION 
Plaintiffs took this appeal from the Ruling on Proposed 
Findings and Objections entered on September 3, 19932 and the 
trial court's judgment entered on September 20, 1993.3 Plaintiffs 
filed their notice of appeal on October 15, 1993.4 Defendant 
GenBio filed its notice of appeal on its cross appeal on October 
28, 1993.5 This Court has jurisdiction of this appeal pursuant to 
Utah Code Ann. §78-2a-3(2)(k).6 
STATEMENT OF ISSUES AND STANDARD OF REVIEW 
Pursuant to Rule 24 (i) of the Utah Rules of Appellate 
Procedure, Ventana and Gephart hereby adopt the "Issues Presented 
and Standard of Review" section of GenBio's Brief. 
DETERMINATIVE PROVISIONS OF LAW 
Counsel is not aware of any constitutional provisions, 
statutes, ordinances or rules which are determinative in this case. 
STATEMENT OF THE CASE 
Pursuant to Rule 24 (i) of the Utah Rules of Appellate 
Procedure, Ventana and Gephart hereby adopt the "Statement of the 
Case" section of GenBio's Brief. 
2Addendum A. 
3Addendum B. 
4R. 1634-35. 
5R. 1639-40. 
6Addendum D. 
2 
SUMMARY OF THE ARGUMENT 
Pursuant to Rule 24 (i) of the Utah Rules of Appellate 
Procedure, Ventana and Gephart hereby adopt the "Summary of the 
Argument" section of GenBio's Brief and also provide the following 
summary of arguments contained in this brief. 
In supplementation of the points argued in GenBio's Brief, 
Ventana and Gephart address four main issues: First, that 
plaintiffs have failed to marshal the evidence; Second, that the 
trial court properly found there was no contract; Third, that any 
purported agreement lacked proper authorization; and, fourth, that 
the trial court's findings are not fatally inconsistent. 
With the exception of one citation to the transcript, 
plaintiffs have failed to marshal the evidence in support of the 
findings of the trial court as required by law. Instead, they have 
merely argued and cited portions of the evidence which support 
their position. This court should therefore "assume that the 
record supports the accuracy of the lower court's conclusions of 
law and the application of that law in the case." Peterson v. 
Peterson.7 
With respect to contract formation issues, Ventana and Gephart 
adopt Section II of GenBio's Brief, "There Is No Contract". If 
this Court affirms the trial court's factual finding that there was 
no meeting of the minds on the essential elements of a purchase 
7818 P.2d 1305, 1307-08 (Utah App. 1991). 
3 
contract in this case, it is unnecessary to consider plaintiffs' 
arguments regarding corporate authority and actual authority. 
Any purported agreement was not authorized by GenBio for two 
reasons. First, there was no board action which authorized any 
purported agreement. There is only one board of directors 
discussion on November 30, 1989 and a later addendum thereto which 
deal with the possible sale of the IFA facility. 
The minutes and the addendum reflect that Gordy (then 
president of GenBio), and only Gordy, was authorized by the board 
to investigate the possible sale of the IFA facility, that he was 
to bring any potential offers to the Board for approval, and that 
in the event of the Board's approval of such a sale, Mr. Gordy 
would be compensated according to the formula set forth in the 
addendum. Nowhere in the language is a contract of sale 
authorized. 
Secondly, Thomas Gephart had neither actual nor apparent 
authority to bind the corporation with respect to any purported 
agreement. Without board authorization, Thomas Gephart, who was 
neither an officer or director of GenBio, lacked corporate 
authority to bind GenBio to any purported agreement. Apparent 
authority is also lacking. Plaintiffs cannot claim that Mr. 
Gephart was clothed with any apparent authority on the basis of any 
office he held with GenBio, because he held none. Further, as two 
of the three directors of GenBio, plaintiffs controlled the votes 
of the GenBio Board. Plaintiffs cannot credibly claim that they 
8R. 1589. 
4 
were somehow misled by their own acts as the majority of the board 
and that defendants are somehow responsible. 
Under the recent Utah Supreme Court case of Luddington v. 
Bodenvest Ltd.,9 a person claiming apparent authority must have 
acted in good faith and in reasonable reliance on the acts which 
constitute the grant of apparent authority. In this case, Condie 
and Yarter, as directors of the board had actual knowledge of 
Gephart's lack of authority to bind GenBio to sell the IFA 
Facility. Furthermore, Gephart advised Condie in writing, in the 
very letter plaintiffs claim constitutes the contract, that a 
contract for the sale of the IFA Facility could only be entered 
into after the proposal was reviewed and approved by GenBio's 
Board.10 Plaintiffs knew that Gephart had no authority and cannot 
reasonably or in good faith assert that Gephart had any apparent 
authority. 
Finally, the trial court's findings are not fatally 
inconsistent. The trial court's findings regarding control which 
plaintiffs rely upon follow the trial court's heading "Proposed 
Findings of Fact and Conclusions of Law on Defendants' 
Counterclaims.n11 Once the trial court granted the defendants' 
Rule 41(b) motion at the end of plaintiffs' case in chief, 
plaintiffs' issues regarding apparent authority and control alleged 
in the Complaint became moot. Ventana, Gephart and Townsen did 
9855 P.2d 204 (Utah 1993). 
10App. Br. Exh. B; Addendum C. 
nR. 1592 (emphasis added). 
5 
have an appropriate degree of influence and involvement with 
GenBio. However, there is nothing sinister or unlawful about this, 
as the court specifically found12 since during the period of time 
that the IFA facility was for sale, Townsen was a director of 
GenBio and Ventana was a 24% shareholder and a primary source of 
funding for GenBio. None of the matters argued by plaintiffs 
establish that Gephart had authority to bind GenBio to any contract 
without board approval. 
ARGUMENT 
Pursuant to Rule 24 (i) of the Utah Rules of Appellate 
Procedure, Ventana and Gephart hereby adopt and incorporate all 
sections of Defendant GenBio's Argument, except for the sections 
dealing with GenBio's counterclaims. Ventana and Gephart provide 
the following supplement to those arguments. 
1^ THE APPEAL SHOULD BE DISMISSED BECAUSE 
PLAINTIFFS/APPELLANTS HAVE FAILED TO MARSHAL THE 
EVIDENCE, 
Pursuant to Rule 24 (i) of the Utah Rules of Appellate 
Procedure, Ventana and Gephart hereby adopt Section I. of GenBio's 
Brief, "The Appeal Should Be Dismissed For Failure to Marshal The 
Evidence" and supplement said section with the following additional 
argument. 
Utah law holds that an appellant must marshal the evidence in 
favor of the findings made by the trial court and then show that 
See R. 1593. 
6 
despite that evidence, the trial court's findings were clearly 
erroneous. In Peterson v. Peterson/13 this Court held, 
We set aside findings of fact only when they are 
clearly erroneous. Utah R. Civ. P. 52(a); Davis v. 
Davis, 749 P.2d 647, 648 (Utah 1988); Ashton v. Ashton, 
733 P.2d 147, 149-50 n.l (Utah 1987). In making that 
determination, we give "due regard" to the "opportunity 
of the trial court to judge the credibility of the 
witnesses." Utah R. Civ. P. 52(a). A finding is clearly 
erroneous when, "although there is evidence to support 
it, the reviewing court on the entire evidence is left 
with the definite and firm conviction that a mistake has 
been committed." State v. Walker, 743 P.2d 191, 193 
(Utah 1987)(quoting United States v. United States Gypsum 
Co., 333 U.S. 364, 395 (1948). In challenging findings, 
the appellant 
must marshal all evidence in favor of the 
facts as found by the trial court and then 
demonstrate that even viewing the evidence in 
a light most favorable to the court below, the 
evidence is insufficient to support the 
findings of fact. If the appellant fails to 
marshal the evidence, the appellate court 
assumes that the record supports the accuracy 
of the lower court's conclusions of law and 
the application of that law in the case. 
Saunders v. Sharp, 806 P.2d 198, 199 (Utah 
1991) . 
The Utah Supreme Court has also stated, 
A party seeking to set aside a trial court's findings 
carries a heavy burden: 
'To mount a successful challenge to the 
correctness of a trial court's findings of 
fact, an appellant must first marshal all the 
evidence supporting the finding and then 
demonstrate that the evidence is legally 
insufficient to support the findings even in 
viewing it in the light most favorable to the 
court below.'14 
13818 P.2d 1305, 1307-08 (Utah App. 1991) 
14Alta Industries Ltd. v. Hurst, 846 P.2d 1282, 1286 (Utah 
1993) (quoting Reid v. Mutual of Omaha Ins., 776 P.2d 896, 899 (Utah 
1989); Grayson Roper Ltd. v. Finlinson, 782 P. 2d 467, 470 (Utah 
7 
With the exception of only one citation to the transcript,15 
plaintiffs have totally failed to marshal the evidence in support 
of the findings of the trial court. Instead, they have merely 
argued and cited portions of the evidence which support their 
position. Plaintiffs do not contend that there was any single, 
specific act by GenBio's board of directors which informed to them 
that Gephart had apparent authority to bind the corporation to sell 
the IFA facility to plaintiffs. Instead, plaintiffs make a 
desperate attempt to claim that Gephart had apparent authority of 
a very general nature to do almost anything on behalf of GenBio 
because he, Duwaine Townsen and Ventana exerted significant control 
over GenBio. Plaintiffs' statement of the facts in their brief in 
this regard is often inaccurate and not only lacks citations to the 
transcript as required by Rule 24(a)(7) of the Utah Rules of 
Appellate Procedure, but also in many instances finds no support 
whatsoever in the record. This is particularly true for the tirade 
of facts regarding the alleged "domination and control" of GenBio 
by Ventana, Gephart and Townsen.16 An example of plaintiffs' 
approach is their statement that "Ventana also has prevented all 
shareholders meetings and has not allowed any information to be 
sent to the shareholders, including financial information."17 The 
actual finding of the court did not attribute these shortcomings to 
1989); In re Estate of Bartell, 776 P.2d 885, 886 (Utah 1998). 
15App. Br, 7. 
16See App. Br. 4-9. 
17R. 1592 (emphasis added). 
8 
Ventana.18 In fact it is important to realize that, during most 
of the critical time periods, both Condie and Yarter were members 
of the GenBio Board. To the extent they are critical of how GenBio 
was run, plaintiffs can also blame themselves. Accordingly, this 
court should "assume that the record supports the accuracy of the 
lower court's conclusions of law and the application of that law in 
the case." Peterson v. Peterson.19 
II, THERE IS NO CONTRACT, 
Pursuant to Rule 24 (i) of the Utah Rules of Appellate 
Procedure, Ventana and Gephart hereby adopts Section II of GenBio's 
Brief, "There Is No Contract". If this Court affirms the trial 
court's factual finding that there was no meeting of the minds on 
the essential elements of a purchase contract in this case,20 it 
18The actual findings of the court in this regard are as 
follows: 
3. The history of the operations of GenBio are 
that there was very little consideration of shareholders' 
interests in the operation of GenBio and that GenBio was 
not run in the manner consistent for providing 
shareholder information. 
4. At no time has GenBio ever conducted any 
shareholders meetings and there have been no election of 
directors by the shareholders in the history of the 
corporation. 
R. 1592-93. 
19818 P.2d 1305, 1307-08 (Utah App. 1991). 
20The trial court held: "The Court finds that the nature of 
the telephone conversations, letters, and subsequent negotiations 
between the parties' attorneys established the parties' intent to 
enter an agreement to negotiate a final contract, but that final 
contract was never signed or agreed upon by the parties." R. 1589. 
9 
is unnecessary to consider plaintiffs' arguments regarding 
corporate authority and actual authority. 
Ill, ANY PURPORTED AGREEMENT WAS NOT AUTHORIZED BY 
GENBIO. 
Pursuant to Rule 24 (i) of the Utah Rules of Appellate 
Procedure, Ventana and Gephart hereby adopt Section III of GenBio's 
Brief, "Any Purported Agreement Was Not Authorized By GenBio" and 
supplement said section with the following additional argument. 
A. There Was No Board Action Which Authorized Any Purported 
Agreement. 
Paragraph 13 of the Bylaws of GenBio21 confers exclusive 
authority to manage the property and business of GenBio on its 
Board.22 Paragraph 16(e) of the GenBio Bylaws states that the 
Board will designate who is authorized to sign a contract on behalf 
of GenBio.23 In the entire record in this case, there is record 
of only one board discussion and a later addendum thereto which 
deal with the possible sale of the IFA facility. The minutes of a 
special meeting of the GenBio board of directors on November 30, 
1989 reflect that: 
A discussion was had concerning the possibilities of 
selling the Company's MRC division. It was the sense of 
the Board that Mr. Gordy [then president of GenBio] 
should investigate the possible sale of this division and 
should bring any potential offers to the Board for 
further discussion and decision.24 
2
 Addendum F. 
22D. Exh. 1. 
23Id. (emphasis added). 
24D. Exh. 53; Addendum G; R. 1585. 
10 
The addendum to these minutes, executed on March 22, 1990, states: 
RESOLVED, that in the event of the sale of the Company's 
Utah division (MRC), John T. Gordy will be remunerated 
for his efforts on the Company's behalf according to the 
following schedule: 
MRC is sold for less than $500,000; no remuneration. 
MRC is sold for $500,000 or greater; Mr. Gordy 
receives five (5%) percent of the net sale 
amount up to a maximum of Fifty Thousand 
($50,000) Dollars.25 
Mr. Gordy testified at trial that he understood the minutes and the 
addendum to authorize the actual sale of the IFA facility without 
further board approval if the sale was for at least $500,000 in 
cash,26 and the trial court agreed with this interpretation.27 
However, the interpretation of the legal effect of documentary 
language such as the board resolution and the addendum are 
questions of law, and this Court can make its own interpretation 
independent of the trial court's determination, based upon a 
correctness standard. In Walter E. Heller Western Inc. v. U.S. 
Rock Wool Co., Inc.,28 this Court stated, "Questions of contract 
interpretation, such as this, are questions of law to which we owe 
no deference but review for correctness."29 The clear language 
of the minutes and the addendum cited above, even taken together, 
do not constitute final authorization of any purported agreement. 
25D. Exh. 53; Addendum H; R. 1585 (emphasis added). 
26June 7 Tr. 32-33, 44 
27R. 1585. 
28787 P.2d 898 (Utah App. 1988). 
29
 Id. at 899. 
11 
Defendants submit that this language simply means that Mr. Gordy, 
and only Mr. Gordy, was authorized by the board to investigate the 
possible sale of the IFA facility, that he was to bring any 
potential offers to the Board for approval, and that in the event 
of the Board's approval of such a sale, Mr. Gordy would be 
compensated according to the formula set forth in the addendum. 
Nowhere in the language is a contract of sale authorized. 
Accordingly, the record is devoid of any board authorization 
of any purported agreement for the sale of the IFA facility. 
B. Thomas Gephart Had Neither Actual Nor Apparent Authority 
To Bind The Corporation With Respect To Any Purported 
Agreement. 
It follows from the foregoing that Thomas Gephart, had no 
actual authority from the board to sell the IFA facility. The 
trial court so found: 
The Court finds that the Board of Directors of GenBio 
never gave Mr. Thomas Gephart authority to enter into a 
contract to sell MRC.30 
The question then becomes whether, as plaintiffs assert, Gephart 
had apparent authority to bind GenBio to sell the IFA facility to 
plaintiffs without board authorization. It is well settled that 
the issue of apparent authority is a factual issue decided by the 
trier of fact.31 The trial court found, "Defendant Gephart did 
30R. 1586. 
31Services Holding Co., Inc. v. Transamerica Occidental Life 
Ins. Co., 1994 WESTLAW 32139 at 7 (Ariz.App. Div.l February 8, 
1994)("the issue of whether [the agent] had apparent authority to 
bind [the principal] is a factual question."); Montoya v. Grease 
Monkey Holding Corp., 1994 WESTLAW 8663 at 2 (Colo. App. March 10, 
1994)("Whether such apparent authority existed is a question of 
fact, and the trial court's determination of this issue is binding 
12 
not have apparent authority to sell MRC or to make a contract to 
sell MRC."32 
1. GenBio Did Not Clothe Gephart With Apparent Authority to 
Bind GenBio to a Sale of Its IFA Facility. 
Utah has long recognized that it is the acts of the principal 
and not the acts of the agent which determine if the agent has 
apparent authority. In City Electric v. Dean Evans Chrysler-
Plymouth,33 the Utah Supreme Court stated, 
It is well settled law that the apparent or ostensible 
authority of an agent can be inferred only from the acts 
and conduct of the principal. Bank of Salt Lake v. 
Corporation of Pres. of Ch., etc., Utah, 534 P.2d 887 
(1975). Where corporate liability is sought for acts of 
its agent under apparent authority, liability is premised 
upon the corporation's knowledge of and acquiescence in 
the conduct of its agent which has led third parties to 
rely upon the agent's actions. Kiniski v. Archway Motel, 
Inc., Wash.App., 21 Wash.App. 555, 586 P.2d 502 (1978); 
Restatement, Agency 2d Sec. 43. Nor is the authority of 
the agent "apparent" merely because it looks so to the 
person with whom he deals. Id. It is the principal who 
must cause third parties to believe that the agent is 
clothed with apparent authority.-3^ 
This principle is similarly recognized in other jurisdictions. In 
Podolan v. Idaho Legal Aid Services, Inc.,35 the Idaho Court of 
Appeals stated, 
if supported by sufficient competent evidence.")(citing 
Heatherridge Management Co. v. Benson, 192 Colo. 190, 558 P.2d 435 
(1976)). 
32R. 1590. 
33672 P.2d 89 (Utah 1983). 
3
*Id. at 90 (emphasis added). See also Zions First Nat'l 
Bank v. Clark Clinic Corp., 762 P.2d 1090, 1095 (Utah 1988). 
35854 P.2d 280, 287 (Idaho App. 1993). 
13 
Apparent authority exists where a principal voluntarily 
places an agent in a position where "a person of ordinary 
prudence conversant with the business usages and the 
nature of the particular business, is justified in 
believing that the agent is acting pursuant to existing 
authority." 
Apparent authority cannot be created by the acts and 
statements of the agent alone. One must use reasonable 
diligence to ascertain the agent's authority. Reasonable 
diligence encompasses a duty to inquire with the 
principal about the agent's authority. If no inquiry is 
made, the third party is chargeable with knowing what 
kind of authority the agent actually had, if any, "and 
the fault cannot be thrown on the principal who never 
authorized the act or contract."Jb 
The Arizona Court of Appeals has similarly held, 
As to apparent authority, "the principal must make some 
manifestation to the third party which could reasonably 
be relied upon to indicate that the agent had the alleged 
authority. ,,JV 
Thomas Gephart was neither an officer nor a director of GenBio 
during December, 1990 and January 1991 when the discussions took 
place with Robert Condie about the possible sale of the IFA 
facility. Gephart had not been a director of GenBio since March of 
1989.38 Condie knew this because he himself was a member of the 
GenBio board of directors from December of 198739 until his 
resignation of December 31, 1990.40 James Yarter was a director 
36Id. (emphasis added). 
31Hartford v. Industrial Commission of Arizona, 870 P.2d 1202, 
1206 (Ariz. App. 1994) . 
38June 8 Tr. 26. 
39June 2 Tr. 239. 
40D. Exh. 36. 
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of GenBio from September 1989 until his resignation on December 13, 
1990.41 He also became Chairman of the Board of GenBio in March 
1990 and became acting president of GenBio in June of 1990.42 
Therefore, plaintiffs cannot claim that Mr. Gephart was clothed 
with any apparent authority on the basis of any office he held with 
GenBio. 
In City Electric v. Dean Evans Chrysler-Plymouth,43 the Utah 
Supreme Court held, 
Moreover, it has been held that apparent authority vanishes 
when the third party has actual knowledge of the real scope of 
the agent's authority.44 
As directors of GenBio, plaintiffs knew there was no formal board 
approval for Gephart to bind the corporation. They knew he was not 
an officer or director of the corporation. And finally, they knew 
that board approval was reguired for significant actions.45 
Furthermore, under the case authority cited above, plaintiffs 
cannot rely on any of Gephart's acts or statements to support their 
argument that Gephart had apparent authority to consummate a deal. 
Therefore, even if Gephart told Condie, as Condie testified, that 
Gephart "was now in charge of [GenBio]" and that if Condie "had any 
further interest in pursuing the purchase of MRC, that [Gephart 
41June 2 Tr. 68. 
*
2Id. 
43672 P.2d at 90, 
44Citing Bank of Oregon v. Highway Products, Or.App., 41 
Or.App. 223, 598 P.2d 318 (1979)). 
45
 See Findings of Fact, 5 10H, R. 1587-88. 
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was] the one [Condie] should contact,"45 it does not matter 
because an agent cannot clothe himself with apparent authority.47 
Plaintiffs' argument that Gephart had apparent authority to 
negotiate and ultimately sell the MRC division is like a dog 
chasing its tail. As shown above, apparent authority can only be 
manifested to a third party from the acts of the principal. As two 
of the three directors of GenBio, plaintiffs controlled the votes 
of the GenBio Board. Yarter was the Chairman of the Board. 
Plaintiffs therefore constituted two-thirds of GenBio's Board, the 
"principal", which they now contend misled them. Incredibly, 
plaintiffs allege that they were somehow misled by their own acts 
as the majority of the board and that defendants are somehow 
responsible. It is anomalous indeed, that plaintiffs contend 
Gephart had apparent authority because their claim amounts to the 
fact that they were both on the "giving" and the "receiving" end of 
the apparent authority issue. 
The trial court was not persuaded by plaintiffs' arguments 
about domination and control because it specifically reviewed each 
action claimed by plaintiffs in their case in chief to support 
their claim of apparent authority and found that "the actions 
alleged by Plaintiffs do not establish unity of interest or 
authority of control giving Mr. Gephart apparent authority.48 
46June 2 Tr. 100; App. Br. 22. 
47City Electric, 672 P.2d at 90, 
48
 A. The contract that Mr. Yarter claimed 
to have had with GenBio was in fact a contract 
with Ventana that did not establish control 
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Based upon these findings the trial court correctly found that: 
"Defendant Gephart did not have apparent authority to sell MRC or 
over GenBio. 
B. The claimed transfer of $200,000 from 
GenBio to Darox to cancel debts was in fact paid to 
Ventana not to Darox in order to retire notes and 
liabilities. The transfer was to an improper transfer by 
GenBio but, rather, was a repayment that was proper. 
C. The Practitioners Agreement [with the 
Swedes] was not evidence of improper control by Ventana 
because the January 14, 1990 Board Minutes reflect Board 
approval of the Practitioners Agreement. 
D. Mr. Gephart's visit to GenBio did not 
establish control of GenBio by Ventana. 
E. The fact that Mr. Monson asked for a 
confirmation from Mr. Gephart as to the terms of his 
separation as reflected in the March 17, 1988 Board 
Minutes did not establish inappropriate control because 
the minutes also reflect that Mr. Gephart was given 
authority from the Board to deal with the issue. 
F. Ventana's investment in GenBio and the 
loans to GenBio did not result in inappropriate control 
over GenBio. There was no evidence presented other than 
that money given to GenBio from Ventana were represented 
by proper notes and warrants. These transactions did not 
reflect payments for control of GenBio but, rather, were 
investments in GenBio. 
G. The move of GenBio's headguarters from 
Salt Lake City to San Diego did not evidence improper 
influence. The overall business plan of the merger 
between Datagene and MRC and the creation of GenBio 
always contemplated that GenBio's headguarters would be 
moved to San Diego. 
H. The Board Meeting of April 30, 1990 where 
Mr. Gephart sat in for Mr. Townsen did not evidence 
improper influence. While the minutes show that Mr. 
Gephart sat in as a representative of Ventana, Mr. 
Gephart did not vote on any of the issues and did not 
take a role as a director in voting on those issues. 
R. 1587-88. 
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to make a contract to sell MRC."4^ The trial court specifically 
found that Gephart did not have the apparent authority alleged by 
plaintiff's in their complaint. 
2. Plaintiffs Did Not Act In Good Faith and Did Not 
Reasonably Rely on the Alleged Appearance of 
Authority. 
The Utah Supreme Court recently decided Luddington v. 
Bodenvest Ltd./50 where the plaintiff successfully argued at trial 
that a principal was liable under the doctrine of apparent 
authority. On appeal, the Utah Supreme Court held that a plaintiff 
asserting that apparent authority exists must show that he "knew of 
the facts and, acting in good faith, had reason to believe, and did 
actually believe, that the agent possessed such authority."51 In 
essence, this means that a person claiming apparent authority must 
have acted in good faith and in reasonable reliance on the acts 
which constitute the grant of apparent authority by the principal. 
In this case, Condie and Yarter had actual knowledge of 
Gephart's lack of authority to bind GenBio to sell the IFA 
Facility. In 1989, the Board authorized its former president, 
Gordy, to investigate the possibility of selling MRC and to "bring 
any potential offers to the Board for further discussion and 
decision." 52 Condie and Yarter were both members of the Board at 
49R. 1590. 
50855 P.2d 204 (Utah 1993). 
slId. at 209. 
52See Minutes of Nov. 30, Defendants' Exhibit 53. 
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the time this direction was given. Thus, plaintiffs were aware 
that no one had authority to enter into a contract to sell the IFA 
Facility without approval of the Board. Gephart advised Condie in 
writing, in the very letter plaintiffs claim constitutes the 
contract, that a contract for the sale of the IFA Facility could 
only be entered into after the proposal was reviewed and approved 
by GenBio's Board.54 This constitutes an admission by Gephart 
that he did not have actual or apparent authority, and plaintiffs 
had notice of his lack of board authority to bind the corporation. 
It is one thing to negotiate a sale; it is quite another thing to 
have the authority to bind a corporation to the sale. As shown in 
Section V of GenBio's Brief, which details GenBio's Counterclaim 
for breach of fiduciary duty, plaintiffs did not act in good faith 
throughout their dealings with GenBio. Plaintiffs knew that 
Gephart had no authority and cannot reasonably or in good faith 
assert that Gephart had any apparent authority. 
IV. THE TRIAL COURT'S FINDINGS ARE NOT FATALLY 
INCONSISTENT. 
Pursuant to Rule 24 (i) of the Utah Rules of Appellate 
Procedure, Ventana and Gephart hereby adopt Section IV of GenBio's 
Brief, "The Trial Court's Findings Are Not Fatally Inconsistent" 
and supplement said section with the following additional argument. 
53ia. 
54App. Br. Exh. B. 
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It is important to view the Findings of Fact and Conclusions 
of Law in the way the trial court did. Note that the trial court's 
findings regarding control which plaintiffs rely upon follow the 
trial court's heading "Proposed Findings of Fact and Conclusions of 
Law on Defendants' Counterclaims."55 Once the trial court granted 
the defendants' Rule 41(b) motion at the end of plaintiffs' case in 
chief, plaintiffs' issues regarding apparent authority56 and 
control57 alleged in the Complaint became moot, and defendants did 
not put on evidence they otherwise might have done. The only 
remaining issues after the trial court granted defendants' Rule 
41(b) motion were whether Gephart had made any negligent 
misrepresentations58 and whether plaintiffs were liable to GenBio 
for breach of fiduciary duty on GenBio's counterclaim. The control 
issue is not implicated by these remaining claims. 
It appears that the trial court, in fashioning its Findings of 
Fact and Conclusions of Law, largely adopted the proposed findings 
and conclusions submitted by the prevailing parties on the claims 
of the Complaint and on the claims of the Counterclaim, 
respectively. Unfortunately, this appears to have resulted in 
findings regarding the issue of control of GenBio on the 
Counterclaim which have no relevance to the allegations of the 
55R. 1592 (emphasis added). 
56Complaint 5 42, R. 9. 
57Complaint 51 56-59, R. 12. 
58Plaintiffs have abandoned this issue on appeal. 
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Counterclaim.59 The findings regarding control of GenBio in the 
"Counterclaim" section of the Findings of Fact and Conclusions of 
Law are not relevant or material to the determination of 
defendants' breach of fiduciary duty claim against plaintiffs 
asserted in the counterclaim. Plaintiffs now attempt to use these 
superfluous findings to support their claims of apparent authority 
in their complaint, but these findings were only adopted by the 
trial court with respect to the counterclaim, and should be 
disregarded when analyzing the plaintiffs' claims.60 Furthermore, 
as argued in GenBio's Brief, plaintiffs are estopped from claiming 
these findings are inconsistent because they represented to the 
trial court that they are not inconsistent with the trial court's 
findings on plaintiffs' claims. 
Ventana, Gephart and Townsen did have an appropriate degree of 
influence and involvement with GenBio. However, there is nothing 
sinister or unlawful about this, as the court specifically 
found.61 Indeed, during the period of time that the IFA facility 
was for sale, Townsen was a director of GenBio. Ventana was a 24% 
shareholder and a primary source of funding for GenBio. The 
claimed inconsistency in the findings is easily harmonized by 
bySee Proposed Findings of Fact and Conclusions of Law on 
Defendants' Counterclaims 55 2-10, 27-38, R. 1592-97. 
60Plaintiffs assured the court below that their proposed 
findings regarding control did not relate to the apparent authority 
issue, but instead related to the breach of fiduciary duty 
counterclaim. R. 1530-42. They are therefore estopped to assert 
these findings in connection with their apparent authority claim. 
61See R. 1593. 
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recognizing that it would be natural for a shareholder and lender 
to exert influence over the corporation; however, plaintiffs failed 
to establish any improper control by Gephart or Ventana which would 
justify reversing the trial court's judgment, 
CONCLUSION 
At its core, this case boils down to the irrefutable fact that 
there was never a meeting of the minds between the parties on the 
essential terms of a contract. The appeal can and should be 
decided on this issue alone, if not on the procedural failure of 
plaintiffs to properly marshal the evidence in favor of the trial 
court's findings. Should this Court decide to reach the remaining 
issues in the case, it is quite clear that any purported agreement 
never was given proper corporate authorization and, in particular, 
Gephart lacked actual or apparent authority as he himself advised 
plaintiffs in his January 10, 1991 letter. Finally, although it 
was unnecessary and irrelevant for the trial court to adopt any 
findings regarding the issue of "control" with respect to GenBio's 
counterclaim, such findings are not inconsistent, as plaintiffs 
themselves argued below. For these reasons, the judgment of the 
trial court should be AFFIRMED. 
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Tab A 
IN THE SECOND DISTRICT COURT OF DAVIS COUNTY J 3- i ,j '33 
STATE OF UTAH t . 
C & Y CORPORATION, ROBERT A. 
CONDIE, AND JAMES YARTER, 
Plaintiffs, 
v. 
GENERAL BIOMETRICS, VENTANA 
GROWTH FUND, AND THOMAS 
GEPHART, 
Defendants. 
'•• ,n: 
RULING ON PROPOSED FINDINGS 
AND OBJECTIONS 
Case No. 910751194 
The Court has reviewed the following information in this case: The Court's ruling of 
the trial, Findings of Fact and Conclusions of Law Regarding Plaintiffs Misrepresentation 
Claim, Plaintiffs Objections to Defendants' Proposed Findings of Fact and Conclusions of 
Law Regarding Plaintiffs' Misrepresentation Claim, Defendant Gephart's Reply to Plaintiffs' 
Objections to Defendant's Proposed Findings of Fact and Conclusions of Law Regarding 
Plaintiffs' Misrepresentation Claim, Plaintiffs Memorandum and Reply to Defendant Gephart's 
Response to Plaintiffs' Objections to Defendants' Proposed Findings of Fact and Conclusions 
of Law Regarding Plaintiffs' Misrepresentation Claim, General Biometrics, Inc.'s Response to 
Plaintiffs' Objection to Proposed Findings of Fact and Conclusions of Law, Plaintiffs' Reply to 
General Biometrics Inc.'s Response to Plaintiffs Objection to Proposed Findings of Fact and 
Conclusions of Law, Findings of Fact and Conclusions of Law, Plaintiffs' Objections to 
Defendants' Proposed Findings of Fact and Conclusions of Law, Proposed Findings of Fact 
and Conclusions of Law on Defendants' Counterclaims, Defendants' Objections to Plaintiffs' 
Proposed Findings of Fact and Conclusions of Law, Plaintiffs' Response to Defendants' 
Objection to Plaintiffs Proposed Findings of Fact and Conclusions of Law, the evidence from 
trial, and the published depositions. The Court makes the following Findings of Fact and 
Conclusions of Law. 
I. 
FINDINGS OF FACT AND CONCLUSIONS OF LAW 
(Submitted by Mary Anne Q. Wood, Anthony B. Quinn and Paul M. Durham) 
FINDINGS OF FACT 
1. Defendant General Biometrics, Inc. ("GenBio"), is a publicly-held corporation 
Defendant Ventana Growth Fund, a California limited partnership ("Ventana"), owns less than 
twenty four percent (24%) of GenBio stock. 
2. At GenBio's Board of Directors Meeting ("Board Meeting") held November 30, 
1989, the Board authorized Mr. John T. Gordy to investigate the possible sale of MRC. The 
Court found the Board of Directors authorized Mr. Gordy to sell MRC Division for $500,000 
or more in a cash sale. For any sale less than $500,000 cash, Mr. Gordy was instructed to 
bring those offers to the Board for further discussion and decision. 
3. An addendum to the November 30, 1989 Board Minutes provided that: 
RESOLVED, that, in the event of the sale of the Company's Utah division (MRC), 
John T. Gordy will be remunerated for his efforts on the Company's behalf according 
to the following schedule: 
MRC is sold for less than $500,000; no remuneration. 
MRC is sold for $500,000 or greater; Mr. Gordy receives five 
(5%) percent of the net sale up to a maximum of Fifty Thousand 
($50,000) Dollars. 
Defendants' Exhibit No. 53. 
4. The Court found based upon testimony that GenBio and Mr. Gordy entered 
into an incentive contract for the sale of MRC. Plaintiff Yarter testified that he was the 
GenBio director who negotiated and drew up the incentive contract and that the approval 
given by GenBio was for a cash sale of MRC for $500,000. This contract was not introduced 
into evidence because it was not found during the discovery process. 
5. Mr. Gordy testified that it was his understanding of the agreement that if the 
sale of MRC were for even a penny less than $500,000, the sale would have to go back to the 
Board for approval. 
6. The Court finds the two letters of January 1991 were not cash sales because the 
January 7th letter from Mr. Condie to Mr. Gephart indicated a purchase price of $500,000 
with $350,000 in cash to be paid upon closing. The $350,000 was later crossed out and a 
figure of $400,000 was inserted. The remainder of the proposed purchase price would be 
paid by Plaintiffs paying $75,000 90 days after closing with an additional $25,000 to be paid 
120 days after closing. 
7. The Court finds there was no contract between GenBio and Plaintiffs because 
the sale of MRC proposed in telephone conversations in December of 1990 and in January of 
1991, and in the letters of January of 1991 were outside the scope of authority given by the 
Board, (i.e. this was not a cash sale in excess of $500,000) and therefore, further Board 
approval, which was required, was not obtained. 
8. The Court finds that the Board of Directors of GenBio never gave Mr. Thomas 
Gephart authority to enter into a contract to sell MRC. 
9. At all material times, Venlana Growth Fund II, L.P., was not a majority 
shareholder of GenBio. All Ventana entities combined own less than twenty four percent 
(24%) of GenBio's stock with just over eleven percent (11% ) in preferred stock held by 
Ventana Growth Fund I, LP., and just over eleven (11%) in common stock held by Ventana 
Growth Fund II, L.P. In addition, Ventana loaned money to GenBio for which it received 
warrants that were convertible into stock. The warrants were not converted into stock and 
therefore, the Court did not find this material in terms of ownership. 
10. The following actions alleged by Plaintiffs do not establish unity of interest or 
authority of control giving Mr. Gephart apparent authority. 
A. The contract that Mr. Yarter claimed to have had with GenBio was in 
fact a contract with Ventana that did not establish control over GenBio. 
B. The claimed transfer of $200,000 from GenBio to Darox to cancel debts 
was in fact paid to Ventana not to Darox in order to retire notes and liabilities. The transfer 
was not an improper transfer by GenBio but, rather, was a repayment that was proper. 
C. The Practitioners Agreement was not evidence of improper control by 
Ventana because the January 14, 1990 Board Minutes reflect Board approval of the 
Practitioners Agreement. 
D. Mr. Gephart's visit to GenBio did not establish control of GenBio by 
Ventana. 
E. The fact that Mr. Monson asked for a confirmation from Mr. Gephart as 
to the terms of his separation as reflected in the March 17, 1988 Board Minutes did not 
establish inappropriate control because the minutes also reflect that Mr. Gephart was given 
authority from the Board to deal with the issue. 
F. Ventana's investment in GenBio and the loans to GenBio did not result 
in inappropriate control over GenBio. There was no evidence presented other than that 
money given to GenBio from Ventana were represented by proper notes and warrants These 
transactions did not reflect payments for control of GenBio but, rather, were investments in 
GenBio. 
G. The move of GenBio's headquarters from Salt Lake City to San Diego 
did not evidence improper influence The overall business plan of the merger between 
Datagene and MRC and the creation of GenBio always contemplated that GenBio's 
headquarters would be moved to San Diego 
H. The Board Meeting of April 30, 1990 where Mr Gephart sat in for Mr 
Townsen did not evidence improper influence While the minutes show that Mr Gephart sat 
in as a representative of Ventana, Mr Gephart did not vote on any of the issues and did not 
take a role as a director in voting on those issues. 
11. Mr. Condie testified that Mr Gephart called him on the 2nd, 3rd or 4th of 
January and offered to sell MRC for $500,000 at $400,000 down with the balance in 60 or 90 
days. 
12. Mr. Condiefs January 7th letter was not an acceptance of the oral offer of Mr 
Gephart's because it varied the terms as to the time of payment and the amount thereof. 
Therefore, there was no meeting of the minds as to the specific terms of the agreement as 
recited between the telephone conversations and the letter of January 7, 1991. 
13. Mr. Gephart's January 10th letter was not an acceptance of the offer contained 
in the January 7th letter because the terms vary on several essential points. First, Gephart's 
letter discussed the sale of assets and liabilities while Condie's letter discussed only the sale 
of assets. The Court received conflicting testimony as to whether the term sale of assets 
includes sale of Board assets and liabilities. Gephart's letter also established a different sale 
price and also established a condition that the plan for the purchase and sale of MRC would 
be taken to the Board within the next week to receive formal approval. 
14. The Court finds that the nature of the telephone conversations, letters, and 
subsequent negotiations between the parties' attorneys established the parties' intent to enter an 
agreement to negotiate a final contract, but that final contract was never signed or agreed 
upon by the parties. 
15. The conduct of the parties and other evidence considered by the Court 
reinforced the Court's finding that a final agreement was not made. The three drafts of the 
agreement and Mr. Condie's testimony in relation to those drafts show that there were several 
essential terms on which the parties did not agree. The parties disagreed as to the non-
competition clause, the allocation of employee related liabilities, consulting arrangements 
between MRC and GenBio, and how accounts receivable and leased equipment would be 
handled. During negotiations, plaintiffs never communicated to defendants that they would 
compromise on these terms. 
CONCLUSIONS OF LAW 
1. Pursuant to Rule 41(b) of the Utah Rules of Civil Procedure defendants are 
entitled to have plaintiffs1 claims against them dismissed with prejudice because after 
completing the presentation of their evidence plaintiffs have shown no right to relief based 
upon the facts and the law. 
2. 41(b) is appropriately invoked when the trial judge finds that the claimant has 
either failed to make out a prima facie case or where the trial judge is not persuaded by the 
evidence presented by the claimant. 
3. When considering a 41(b) motion, the Court is allowed a certain latitude to 
weigh the evidence and draw inferences therefrom. 
4. Because the evidence presented by plaintiffs is insufficient to make out a prima 
facie case the Court is required to enter a decision for defendants on their motion for 
dismissal under Rule 41(b) of the Utah Rules of Civil Procedure. 
5. Defendant Gephart did not have actual authority to sell MRC or to make a 
contract to sell MRC. 
6. Defendant Gephart did not have apparent authority to sell MRC or to make a 
contract to sell MRC. 
7. The circumstances of this case show that the conversations in December of 
1990 and January of 1991, and the letters exchanged in January of 1991 were preliminary 
negotiations to enter a contract and were not a final agreement or contract. 
8. It is not necessary that the contract itself contain all the particulars of the 
agreement. The crucial question is whether the parties agreed on the essential terms of the 
contract. 
9. Extrinsic evidence considered by the Court to delineate the intent of the parties 
and the enforceability of the contract established that the minds of these parties did not meet 
on essential terms. 
10. The correspondence and draft agreements and additional testimony establish 
that the parties did not mutually agree on the contract essential terms. 
11. While plaintiffs placed a great deal of reliance on Rand Whitney Packaging 
Corp. v. The Robertson Group. Inc . 651 F. Supp. 520 (D. Mass. 1986), there are substantial 
differences between some key elements of the Rand Whitney case and this case. Particularly, 
the parties in Rand Whitney engaged in extensive negotiations in which they dealt with many 
of the specific details for making the agreement prior to making the contract. In this case, 
plaintiffs did not present evidence that such details had been agreed upon prior to the time the 
contract was alleged to have been made. The package of information developed by GenBio 
to give to potential purchasers of MRC was not evidence of agreed upon terms because the 
package was not part of any specific negotiations between the parties. 
12. Of major importance to this court is the difference in conduct of the seller in 
Rand Whitney and the seller in this case. In Rand Whitney, after the seller had made the 
offer it told prospective purchasers the company had been sold and the company otherwise 
conducted itself as if the sale had actually taken place. In this case, GenBio's conduct 
indicated that MRC was still for sale. GenBio continued to negotiate the sale of MRC with 
parties other than plaintiff. In late December of 1990 and in January of 1991, Mr. Dorsett 
had conversations with GenBio and Mr. Townsen regarding Dorsett's potential purchase of 
MRC. The conversations and all activities taking place between Mr. Dorsett and GenBio 
indicated that MRC was still for sale. And while Mr. Dorsett was told that an offer was on 
the table, Mr. Dorsett and GenBio continued to negotiate the purchase and sale of MRC. 
13. Another difference between Rand Whitney and the present case relates to the 
board approval given in these cases. In Rand Whitney a specific proposal to sell to a specific 
company was taken to the board of directors. The board approved the specific sale for a 
specific dollar amount to a specific company. It was not a general approval to sell to anyone 
within the terms. The Court in Rand Whitney went into great detail in establishing why it 
believed the board actually approved the specific sale at issue and that the minds of the 
parties had met. However, there is a significant factual distinction between the Rand Whitney 
case and the case presented by plaintiffs in this case. The only agreement reached in the 
present matter was an agreement to negotiate a final purchase and sale contract. With respect 
to these negotiations, this Court makes the assumption that they were made in good faith 
14. Since no contract to sell MRC was ever formed between the parties, the issues 
of specific performance, lost profits and reverse piercing of the corporate veil are moot and 
will not be decided by the Court. 
15. The Court reserves and does not decide the issue of adequacy of tender as the 
defendants failed to include that issue in the pre-trial order and the Court doesn't feel that 
issue is properly before the Court 
II. 
PROPOSED FINDINGS OF FACT AND CONCLUSIONS OF LAW ON 
DEFENDANTS' COUNTERCLAIMS 
FINDINGS OF FACT 
1. GenBio is a Delaware Corporation with its principal place of business located 
in California. They also have a separate facility located in Bountiful, Utah. 
2. Defendant Ventana Growth Fund ("Ventana") is a California Limited 
partnership with its principal place of business located in California and is a major 
shareholder of GenBio. The managing partners of Ventana are Defendant Thomas Gephart 
and Duwaine Townsen. 
3. The history of the operations of GenBio are that there was very little 
consideration of shareholders' interests in the operation of GenBio and that GenBio was not 
run in the manner consistent for providing shareholder information. 
4. At no time has GenBio ever conducted any shareholders meetings and there 
have been no election of directors by the shareholders in the history of the corporation. 
5. Mr. Gephart and Mr. Townsen exercised a great deal of control over the 
GenBio Board of Directors and the operation of GenBio, however, this influence did not rise 
to the level of being a violation of law. 
6. With the exception of Mr. Condie, all of the GenBio directors were either 
employees of Ventana, consultants who had a relationship with Ventana, shareholders with 
another portfolio company of Ventana, or GenBio employees. The appointment of all 
directors were at the direction of Mr. Gephart or Mr. Townsen. Mr. Gephart or Mr. Townsen 
controlled who subsequent directors would be and controlled the appointment of the directors 
in this case. 
7. Many of the decisions to hire key personnel, rather than being made by the 
GenBio Board of Directors independently, were made either by Mr Gephart or Mr. Townsen 
Mr. Gordy, who was hired as president, was instructed to talk to Mr. Gephart and Mr. 
Townsen rather than deal with Mr. Monson, who was the CEO of GenBio. At this time, Mr 
Gephart was neither a director nor an officer of GenBio 
8. When there was a dispute between the officers, it was Mr. Gephart who was 
involved in the resolution of the dispute, not the Board of Directors. This included a dispute 
between Mr. Yarter and Mr. Monson, which resulted in the decision to terminate Mr. 
Monson. This decision was made by Mr. Gephart and not the Board of Directors. 
9. In considering the evidence adduced on whether Mr. Gephart or the Board 
made this decision, and the testimony of Mr. Gephart on what has happened in GenBio in 
general, the Court has serious reservations on the credibility of Mr. Gephart's testimony. Mr 
Gephart had substantial influence in the operation of GenBio, but has little, if no, recollection 
on what has occurred. 
10. Mr. (jephart and Mr. Townsen had a great deal of control in the decision when 
to recall loans and the time of payments, rather than the GenBio Board of Directors, or 
independent officers, being able to control when money was sent. The decisions to recall 
loans and the timing of payments were made in the best interests of Ventana, rather than the 
best interests of GenBio. 
11. Robert A. Condie was a member of the GenBio Board of Directors from July 
1987 until December 31, 1990. 
12. Mr. Yarter served on the GenBio Board of Directors from November 1989 until 
November 30, 1990. 
13. Although Mr Condie was a director when he first contacted Mr. Townsen to 
make an offer to purchase the MRC Division, Mr. Condie specifically resigned from the 
Board so that he could enter subsequent negotiations for the purchase and sale of MRC 
Division and consummate an agreement. 
14. Mr. Yarter resigned from the Board prior to the time when any offers for the 
purchase and sale of the MRC Division were made. 
15. Even after resigning from the Board of Directors in November 1990, Mr. 
Yarter introduced Dr. Preston Dorsett to GenBio for the purpose of Dr. Dorsett negotiating for 
the purchase and sale of the MRC Division. 
16. When Mr. Condie rented his condominium in Park City, Utah to GenBio, there 
was a benefit to the corporation rather than an abuse of corporate authority. Three people 
were occupying the condominium for approximately $125 a week. 
17. The receipt by Mr. Condie of health insurance provided by GenBio was not an 
abuse of discretion and did not constitute an improper benefit It appeared to be a custom 
and practice of this corporation to provide such benefits 
18 Mr Condie as a director regularly requested that shareholder meetings be held 
as required by the By-Laws 
19 Other benefits also were provided to Board members, the board minutes of 
November 30, 1989 show that the Board took action to provide Ventana a $2,000 per month 
consulting fee for prior service for approximately eight to fifteen months based on the fact 
that Mr townsen had put in excess time prior to that 
20 The information Mr Condie or Mr Yarter obtained in making their decision to 
pursue the purchase of the MRC Division was not of a confidential nature and was the same 
information which had been sent to other potential purchasers The information which Mr 
Condie of Mr Yarter received also was the same information sent to Dr Dorsett 
21 Prior to the time Mr Condie and Mr Yarter had any interest in purchasing the 
MRC Division, the GenBio Board of Directors authorized its sale for $500,000 cash in 
November 1989 
22 Information relating to the MRC Division, including financial information, was 
segregated for the express purpose of providing this information to prospective purchasers 
23 During the November 30, 1989 Board meeting, the Board of Directors gave 
Mr Gordy approval to sell MRC for $500,000 or more and that Mr Gordy would receive a 
five percent commission for the sale of the MRC Division Mr Gephart and Mr Townsen 
also gave their approval to sell the MRC Division prior to the November 30, 1989 meeting 
24 Mr Gordy's testimony indicated that he regularly marketed the sale of MRC 
for a six to eight month period 
25. Mr. Gordy met regularly with Mr. Gephart and Mr. Townsen and reported to 
them on the sale of the MRC Division. 
26. GenBio's reasons for desiring to sell MRC were to raise capital for the 
development of the ImmunoDot technology, which was the future of GenBio. The IFA 
technology, of which the MRC Division consisted, was an antiquated technology and in a 
harvest mode. 
27. Subsequent to this Board meeting, GenBio entered into listing agreements with 
Geary Berlew, Waldon & Associates and Ventura, which was a business associate of Mr. 
Gephart. The listing agreement with Ventura was entered at the request of Mr. Gephart. 
28. Although Mr. Gephart did not have actual authority to sell MRC he had 
substantial knowledge of GenBio and the MRC Division and was involved in negotiations to 
sell the MRC Division, even though he was not a member of the GenBio Board. 
29. Other efforts to sell the MRC Division include negotiations with Dr. Dorsett. 
Dr. Dorsett initially contacted Mr. Townsen, but Mr. townsen referred him to Mr. Gephart. 
30. Dr. Dorsett indicated to Mr. Gephart that his company was prepared to make 
an offer for the purchase and sale of the MRC Division in the range of $500,000 to $600,000 
and that they would like to send one of their employees to MRC to perform due diligence. 
31. Mr. Gephart stated to Dr. Dorsett at that time that an in-house offer in the 
same range was on the table and that Dr. Dorsett needed to act quickly if he was interested in 
purchasing MRC. 
32. Dr. Dorsett did not believe he could meet the restrictions and time table set by 
Mr. Gephart and withdrew his offer. 
33. The Board of Director's approval for the sale of MRC has never been rescinded 
by any subsequent Board or Board meeting. 
34. The MRC Division clearly was for sale beginning in November of 1989 Prior 
approval of that sale also had been obtained from both Mr. Gephart and Mr. Townsen prior to 
it going to the Board of Directors for approval. 
35. The business opportunity and information regarding the potential of MRC had 
been available to GenBio and its officers, and particularly in this case, had been available to 
Mr. Gephart and Mr. Townsen. Mr. Gephart and Mr. Townsen had available to them the 
same knowledge and information that was available to Mr. Condie and Mr. Yarter. 
36. Every six months, Mr. Gephart and Mr. Townsen performed a full evaluation 
of each of the business opportunities of their portfolio companies, including GenBio. 
37. The same information also was fully disclosed to Mr. Gephart and Mr. 
Townsen on at least a bimonthly basis. 
38. Mr. Gephart, although not a board member, was present at the April 30, 1990 
Board meeting wherein Mr. Gordy gave a report to the Board of the possible sale of MRC. 
Mr. Gephart was present at this meeting in Mr. townsen's absence as a representative of 
Ventana. Mr. Gephart requested that he be sent copies of all sales literature and material 
which was sent to potential purchasers. Mr. Gordy also reported at this meeting that 
information regarding MRC had been segregated for potential buyers. 
CONCLUSIONS OF LAW 
1. The Court adopted the following legal standards in reaching conclusions of 
law. 
A. Pursuant to the fiduciary duty of loyalty, the corporate opportunity 
doctrine forbids a corporate director from acquiring for his own benefit an opportunity that 
would have been valuable and germane to the corporation's business, unless that opportunity 
is first presented to the corporation and it is declined by a disinterested board of directors, or, 
where that is not possible, by action of the stockholders. 
B. The doctrine of corporate opportunity forbids a corporate director from 
acquiring for his own benefit an opportunity that would have been valuable and germane to 
the corporation's business, unless that opportunity is first offered to the corporation and 
declined. 
2. Counterclaim plaintiff has not shown that Mr. Condie or Mr. Yarter breached 
any fiduciary duties when they decided to investigate the possible purchase of the MRC 
Division. 
3. Counterclaim plaintiff has not shown that Mr. Condie or Mr. Yarter gained 
access to, or improperly used, confidential information of GenBio to establish a competing 
corporation and urging GenBio to sell the MRC Division in such a manner that would have 
been detrimental to GenBio and its stockholders. 
4. Counterclaim plaintiff has not shown that Mr. Condie or Mr. Yarter diverted 
or attempted to divert to themselves opportunities which in fairness and equity belonged to 
GenBio. 
5. The Court finds it doesn't need to raise the question to pierce the corporate veil 
because of the Court's previous findings. 
III. 
FINDINGS OF FACT AND CONCLUSIONS OF LAW 
REGARDING PLAINTIFFS MISREPRESENTATION CLAIM 
FINDINGS OF FACT 
1. The Court finds from the testimony of Plaintiff Robert Condie ("Condie ") that 
on December 22, 1990. defendant Thomas Gephart ("Gephart") called Condie at his home 
and told Condie that Gephart was in charge of Ventana (which the Court believes Condie 
really meant to say "GenBio"), that Duwaine Townsen ("Townsen") was "burned out", that 
Gephart was going to reorganize the board of directors of defendant General Biometrics, Inc 
("GenBio"); and if Condie had any further interest in pursing the purchase of MRC that 
Gephart was the one Condie should contact 
2. During that conversation, Gephart told Condie that at a multiple of two or three 
times earnings, GenBio may be worth one million to two million dollars, that Gephart knew 
that Condie knew that Gephart was the manning running Ventana (GenBio) and MRC, and 
that the board would — the new board would be a perfunctory thing, and that if Condie had 
an interest that they should get together 
3. The Court also finds the foregoing conversation consistent with Condie's 
version of the conversation in his deposition testimony at page 78 of his deposition, namely 
that Gephart informed Condie that Townsen was no longer the chairman of the board, that 
Gephart had taken over as chairman; that Townsen was burned out, and that Gephart was 
going to appoint some new directors that had some pizazz and some high visibility, that any 
dealings that Condie would want to do as far as the purchase of MRC should be done through 
Gephart; and that as the chairman of the board and the general partner of Ventana that 
Gephart was in a position to consummate a deal and asked Condie for an offer; that the board 
as it was and as it would be was a perfunctory thing, that Condie knew that Gephart 
controlled and would make the decisions for General Biometrics. 
4. On January 10, 1991, Gephart sent Condie a letter in which he sated: "I will 
plan to take this proposal to the GenBio Board of Directors within the next week, to receive 
formal approval." 
5. The statements made by Gephart to Condie on December 22, 1990 and in his 
letter of January 10, 1991, were made in good faith at the time they were made and Gephart 
at that time intended to follow through on those statements. 
6. During subsequent negotiations which occurred during the months of January 
through March 1991, GenBio and plaintiffs were never able to agree on essential terms of an 
agreement and board approval by GenBio for the proposed sale of MRC was never given. 
7. Gephart expected plaintiffs to rely on his representations of authority to sell the 
MRC Division and the plaintiffs did in fact reasonably rely on those representations. Based 
on the representations of Gephart, the plaintiffs hired legal counsel, and incurred costs 
thereby, to draft a purchase and sale agreement, and that the legal counsel hired by plaintiffs 
did communicate with counsel for GenBio and other corporate officers. Based on the 
representations of Gephart, plaintiffs also incurred costs in obtaining financing to purchase the 
MRC Division. The Court finds that these representations and discussions were in the nature 
of negotiations to reach a final contract rather than making a final agreement to sell. 
CONCLUSIONS OF LAW 
1. The Court finds the standard the standard applicable to the plaintiffs' cause of 
action for negligent misrepresentation is stated in the Utah Supreme Court case of Jardine v. 
Brunswick Corp.. 423 P.2d 659 (Utah 1967), as follows: 
Where one having a pecuniary interest in a transaction, is in a superior position 
to know material facts, and carelessly or negligently makes a false representation 
concerning them, expecting the other party to rely and act thereon, and the other party 
reasonably does so and suffers loss in that transaction, the representor can be held 
responsible if the other elements of fraud are also present. 
Id at 662 (citing Pace v. Parrish. 122 Utah 247 P 2d 273 (Utah 1952). 
2. The statements made by Gephart, and particularly that "the board was a 
perfunctory thing or perfunctory purpose" and his implicit promise to obtain board approval 
do not constitute negligent misrepresentations under the definition set down by the case of 
Cerritos Trucking Co. v Utah Venture No 1. 645 P 2d 608 (Utah 1982). In Cerntos, the 
Utah Supreme Court stated that there is no negligent misrepresentation "when the promisor's 
expression of intention to perform is made in good faith even though he may have been 
negligent in assessing and weighing the various factors which influenced him in formulating 
that intention." Id. at 612. 
3. Gephart's statement that he would get board approval and that it would be 
perfunctory was consistent with his January 10 letter that he would present Condie's offer to 
the board and get board approval The Court finds that the promise or statement made in this 
case falls within the facts of the Cerntos case. In that case, the Utah Supreme Court stated 
that where a promise is made in good faith, there is no fraud if "the promisor subsequently 
changes his mind and fails or refuses to perform " Id. at 612. 
4. The Court finds in this case that there was a good faith promise made by 
Gephart to obtain board approval, however, because of the subsequent negotiations in which 
the parties could not agree on essential terms as evidenced by the testimony of Mr. EHson and 
Mr. Flodin, there never was a meeting of the minds on essential terms of a contract. 
Therefore, there was no agreement. Based on that finding and on the March 6, 1991 GenBio 
board meeting, at which time there was not approval, the Court finds that there was a change 
of mind by Gephart whereby he failed or refused to perform. 
5. Plaintiffs claim for negligent misrepresentation against Gephart is hereby 
denied based upon plaintiffs' failure to establish any misrepresentation as to any past or 
present material fact or a present promise which Gephart did not intend to perform at the t 
it was made. 
Dated this 3 ^ day of S e p ^ . . , 1993. 
BY THE COURT 
_J frv^- ttYttWJr 
DISTRICT COURT JUDGE 
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IN THE SECOND JUDICIAL DISTRICT COURT IN AND FOR DAVIS COUNTY 
STATE OF UTAH 
CSY CORP., a Utah corporation, 
ROBERT A. CONDIE, an individual, 
and JAMES YARTER, an individual, 
Plaintiffs, ; 
V, 
GENERAL BIOMETRICS, INC., a 
Delaware corporation; VENTANA 
GROWTH FUND, a California 
limited partnership, and THOMAS 
GEPHART, an individual, 
Defendants. ] 
JUDGKENT 
i Civil No. 910751194 
Judge Jon ML Memmott 
This action came on for trial before the above-entitled 
court with Honorable Jon M. Memmott, District Judge presiding. 
The issues having been duly tried and the court having rendered 
its findings of fact and conclusions of law, 
IT IS ORDERED AND ADJUDGED: 
That the plaintiff take nothing on its complaint, that 
the complaint be dismissed on the merits; 
That defendant take nothing on its counterclaim/ that 
the counterclaim be dismissed on the merits; and 
n\ r V" ' 
riLETr IN CLARK'S Or?iC!T 
fi.V/;:, • /••-• • T> • 
SEP 20 II on Ml *93 
r 4 / 
CL*ihK. d!u* w/V..CC'JKr 
«_**£ 
DEPUTY CLIZK* 
That each party shall bear its own costs and attorneys' 
fees. 
DATED this 1 p*1 day of September, 1993. 
BY THE COURT: 
Honorable Jon M. Mejwnott 
2 
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U.S. mail; postage prepaid, a true and correct copy of the 
foregoing Judgment this ^£J£-day of September, 19 93, to the 
following: 
Robert S. Campbell, Jr., Esq. 
Paul T. Moxley, Esq. 
Robert E. Mansfield, Esq. 
Campbell Maack & Sessions 
One Utah Center, Thirteenth Floor 
201 South Main Street 
Salt Lake City, Utah 84111 
Paul M* Durham, Esq. 
DURHAM, EVANS & JONES 
1200 Beneficial Life Tower 
36 South State Street 
Salt Lake City, Utah 84111 
bk;ADOP\JUDGMENT.OHN 
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Via Facsimile: (801) 363-1588 
January 10, 1991 
Mr. Robert Condi* 
BRIGHTON HOSPrrALITY GROUP 
50 South 400 East 
Suite 116 
Salt Lake City, UT 84111 
Dear Bob: 
Pursuant to your January 7 correspondence and to our telephone conversation yesterday 
afternoon, I would like to provide a written acknowledgement of the agreement regarding 
the sale of assets and liahflrriri of MRC from GenBio for $500,000. As I mentioned, we 
generally agree with your proposal. 
Please note, however, that the capital amounts in Sections (B), (C) and (D) of your proposal 
only total 5450,000. In mis regard, I would like to modify section (B) to be increased to 
$400,000 - instead of 5350,000 - so that the total will add up to the entire S500,000. .1 
will plan to take this proposal to the GenBio Board of Directors within the next week, to 
receive formal approval. 
I will look forward to speaking with you shortly. 
Sincerely yours, 
VENTANA 
Thomas O. Gephart 
Managing Partner 
TOGAck 
_ A£«C :<tc Scr* '.><£.* ;>«*• Suae TOO • *«r\ D^jo. CA v2'03 • \uV*)?$»2W * AXfaW) 7*5*£10^ 
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78-2a-3 JUDICIAL CODE 
a successor is appointed and qualified. The presiding 
judge of the Court of Appeals shall receive as addi-
tional compensation $1,000 per annum or fraction 
thereof for the period served. 
(2) The Court of Appeals shall sit and render judg-
ment in panels of three judges. Assignment to panels 
shall be by random rotation of all judges of the Court 
of Appeals. The Court of Appeals by rule shall pro-
vide for the selection of a chair for each panel. The 
Court of Appeals may not sit en banc. 
(3) The judges of the Court of Appeals shall elect a 
presiding judge from among the members of the court 
by majority vote of all judges. The term of office of the 
presiding judge is two years and until a successor is 
elected. A presiding judge of the Court of Appeals 
may serve in that office no more than two successive 
terms. The Court of Appeals may by rule provide for 
an acting presiding judge to serve in the absence or 
incapacity of the presiding judge. 
(4) The presiding judge may be removed from the 
office of presiding judge by majority vote of all judges 
of the Court of Appeals. In addition to the duties of a 
judge of the Court of Appeals, the presiding judge 
shall: 
(a) administer the rotation and scheduling of 
panels; 
(b) act as liaison with the Supreme Court; 
(c) call and preside over the meetings of the 
Court of Appeals; and 
(d) carry out duties prescribed by the Supreme 
Court and the Judicial Council. 
(5) Filing fees for the Court of Appeals are the 
same as for the Supreme Court. 1988 
78-2a-3. Cour t of Appea l s jur i sd ic t ion . 
(1) The Court of Appeals has jurisdiction to issue 
all extraordinary writs and to issue all writs and pro-
cess necessary: 
(a) to carry into effect its judgments, orders, 
and decrees; or 
(b) in aid of its jurisdiction. 
(2) The Court of Appeals has appellate jurisdiction, 
including jurisdiction of interlocutory appeals, over: 
(a> the final orders and decrees resulting from 
formal adjudicative proceedings of state agencies 
or appeals from the district court review of infor-
mal adjudicative proceedings of the agencies, ex-
cept the Public Service Commission, State Tax 
Commission, Board of State Lands, Board of Oil, 
Gas, and Mining, and the state engineer; 
(b) appeals from the district court review of: 
(i) adjudicative proceedings of agencies of 
political subdivisions of the state or other lo-
cal agencies; and 
(ii) a challenge to agency action under 
Section 63-46a-12.1; 
(c) appeals from the juvenile courts; 
(d) appeals from the circuit courts, except 
those from the small claims department of a cir-
cuit court; 
(e) interlocutory appeals from any court of 
record in criminal cases, except those involving a 
charge of a first degree or capital felony; 
(f) appeals from a court of record in criminal 
cases, except those involving a conviction of a 
first degree or capital felony; 
(g) appeals from orders on petitions for ex-
traordinary writs sought by persons who are in-
carcerated or serving any other criminal sen-
tence, except petitions constituting a challenge to 
a conviction of or the sentence for a first degree 
or capital felony; 
398 
(h) appeals from the orders on petitio 
traordinary writs challenging the decisinS f°r e** 
Board of Pardons except in cases involvi°nS°fl^ 
degree or capital felony; ^afir^ 
(i) appeals from district court involve 
tic relations cases, including, but not i, ^ 
divorce, annulment, property division c h ^ t°-
tody, support, visitation, adoption, and nat Cu*" 
(j) appeals from the Utah Military C0u y 
(k) cases transferred to the Court of A ar^ 
from the Supreme Court. p p ealj 
(3) The Court of Appeals upon its own moti 
and by the vote of four judges of the court mav n °n^ 
to the Supreme Court for original appellate T^ 
and determination any matter over which the n"1** 
of Appeals has original appellate jurisdiction °Un 
(4) The Court of Appeals shall comply with th 
quirements of Title 63, Chapter 46b, in its revi * *" 
agency adjudicative proceedings. w °^  
78-2a-4. Review of ac t ions by Supreme Co 
Review of the judgments, orders, and decrees of tk 
Court of Appeals shall be by petition for writ of «»*.* 
orari to the Supreme Court. °fcerti. 
78«2a-5. Location of Court of Appeals. 
The Court of Appeals has its principal location 
Salt Lake City. The Court of Appeals may perform 
any of its functions in any location within the state 
i * 
CHAPTER 3 
DISTRICT COURTS 
Section 
78-3-1 to 78-3-2. Repealed. 
78-3-3. Term of judges — Vacancy. 
78-3-4. Jurisdiction — Transfer of cases to cir-
cuit court — Appeals — Jurisdiction 
when circuit and district court 
merged. 
78-3-5. Repealed. 
78-3-6. Terms — Minimum of once quarterly 
78-3-7 to 78-3-11. Repealed. 
78-3-11.5. State District Court Administrative 
System. 
78-3-12. Repealed. 
78-3-12.5. Costs of system. 
78-3-13. Repealed. 
78-3-13.4. Counties joining court system — Pro-
cedure — Facilities — Salaries. 
78-3-13.5, 78-3-14. Repealed. 
78-3-14.5. Allocation of district court fees and 
fines. 
78-3-15 to 78-3-17. Repealed. 
78-3-17.5. Application of savings accruing to 
counties. 
78-3-18. Judicial Administration Act — Short 
title. 
78-3-19. Purpose of act. 
78-3-20. Definitions. 
78-3-21. Judicial Council — Creation — Mem-
bers — Terms and election — Re-
sponsibilities — Reports. 
78-3-21.5. Data bases for judicial boards. 
78-3-22. Presiding officer - - Compensation -
Duties. 
78-3-23. Administrator of the courts — Ap-
pointment — Qualifications — Sal-
ary. 
78-3-24. Court administrator — Powers, du-
ties, and responsibilities. 
TabE 
same standards as the review of findings of fact in other appeals. 
(Added effective October 1, 1992.) 
NOTES TO DECISIONS 
Allegation of facts required. to remand a claim under this rule for a fishmp 
Because defendant did not allege any facts in expedition State v. Garrett. 849 P.2d 573 
support of his ineffective assistance claim, the (Utah Ct. AppJ, cert, denied, 860 P. 943 (Utah 
appellate court would not remand the case for 1993). 
an evidentiary hearing. It would be improper 
Rule 24. Briefs. 
(a) Brief of the appellant. The brief of the appellant shall contain under 
appropriate headings and in the order indicated: 
( D A complete list of all parties to the proceeding in the court or 
agency whose judgment or order is sought to be reviewed, except where 
the caption of the case on appeal contains the names of all such parties. 
The list should be set out on a separate page which appears immediately 
inside the cover. 
(2) A table of contents, with page references. 
(3) A table of authorities with cases alphabetically arranged and with 
parallel citations, rules, statutes and other authorities cited, with refer-
ences to the pages of the brief where they are cited. 
(4) A brief statement showing the jurisdiction of the appellate court. 
(5) A statement of the issues presented for review and the standard of 
appellate review with supporting authority for each issue. 
(6) Constitutional provisions, statutes, ordinances, rules, and regula-
tions whose interpretation is determinative shall be set out verbatim with 
the appropriate citation. If the pertinent part of the provision is lengthy, 
the citation alone will suffice, and in that event, the provision shall be set 
forth as provided in paragraph (f) of this rule. 
(7) A statement of the case. The statement shall first indicate briefly 
the nature of the case, the course of proceedings, and its disposition in the 
court below. A statement of the facts relevant to the issues presented for 
review shall follow. All statements of fact and references to the proceed-
ings below shall be supported by citations to the record in accordance with 
paragraph (e) of this rule. 
(8) Summary of arguments. The summary of arguments, suitably 
paragraphed, shall be a succinct condensation of the arguments actually 
made in the body of the brief. It shall not be a mere repetition of the 
heading under which the argument is arranged. 
(9) An argument. The argument shall contain the contentions and rea-
sons of the appellant with respect to the issues presented, with citations 
to the authorities, statutes, and parts of the record relied on. 
(10) A short conclusion stating the precise relief sought. 
(b) Brief of the appellee. The brief of the appellee shall conform to the 
requirements of paragraph (a) of this rule, except that a statement of the 
issues or of the case need not be made unless the appellee is dissatisfied with 
the statement of the appellant. 
(c) Reply brief. The appellant may file a brief in reply to the brief of the 
appellee, and if the appellee has cross-appealed, the appellee may file a brief 
in reply to the response of the appellant to the issues presented by the cross-
appeal. Reply briefs shall be limited to answering any new matter set forth in 
the opposing brief. The content of the reply brief shall conform to the require-
ments of paragraph (a)(2), (3), (6), (9), and (10) of this rule. No further briefs 
may be filed except with leave of the appellate court. 
(d) References in briefs to parties. Counsel will be expected in their 
briefs and oral arguments to keep to a minimum references to parties by such 
designations as "appellant" and "appellee." It promotes clarity to use the 
designations used in the lower court or in the agency proceedings, or the 
4 09 UTAH RULES OF APPELLATE PROCEDURE Rule 24 
actual names of parties, or descriptive terms such as "the employee," "the 
injured person," "the taxpayer," etc. 
(e) References in briefs to the record. References shall be made to the 
pages of the original record as paginated pursuant to Rule 1Kb), to pages of 
the reporter's transcript, or to pages of any statement of the evidence or 
proceedings or agreed statement prepared pursuant to Rule 11(0 or 11(g). 
References to exhibits shall include exhibit numbers. If reference is made to 
evidence the admissibility of which is in controversy, reference shall be made 
to the pages of the transcript at which the evidence was identified, offered, 
and received or rejected. 
(0 Reproduction of statutes, rules, regulations, documents, etc. If de-
termination of the issues presented requires the study of statutes, rules, regu-
lations, etc., or relevant parts thereof, to the extent not set forth under sub-
paragraph (a)(6) of this rule, they shall be reproduced in the brief or in an 
addendum at the end, or they may be supplied to the court in pamphlet form. 
Copies of those parts of the record on appeal that are of central importance to 
the determination of the appeal (e.g., the challenged instructions, findings of 
fact and conclusions of law, memorandum decision, the contract or document 
subject to construction, etc.) shall also be included in the addendum. 
(g) Length of briefs. Except by permission of the court, principal briefs 
shall not exceed 50 pages, and reply briefs shall not exceed 25 pages, exclusive 
of pages containing the table of contents, tables of citations and any adden-
dum containing statutes, rules, regulations, or portions of the record as re-
quired by paragraph (f) of this rule. 
(h) Briefs in cases involving cross-appeals. If a cross-appeal is filed, the 
party first filing a notice of appeal shall be deemed the appellant for the 
purposes of this rule and Rule 26, unless the parties otherwise agree or the 
court otherwise orders. The brief of the appellee shall contain the issues and 
arguments involved in the cross-appeal as well as the answer to the brief of 
the appellant. 
(i) Briefs in cases involving multiple appellants or appellees. In cases 
involving more than one appellant or appellee, including cases consolidated 
for purposes of the appeal, any number of either may join in a single brief, and 
any appellant or appellee may adopt by reference any part of the brief of 
another. Parties may similarly join in reply briefs. 
(j) Citation of supplemental authorities. When pertinent and significant 
authorities come to the attention of a party after that party's brief has been 
filed, or after oral argument but before decision, a party may promptly advise 
the clerk of the appellate court, by letter setting forth the citations. An origi-
nal letter and nine copies shall be filed in the Supreme Court. An original 
letter and seven copies shall be filed in the Court of Appeals. There shall be a 
reference either to the page of the brief or to a point argued orally to which the 
citations pertain, but the letter shall without argument state the reasons for 
the supplemental citations. Any response shall be made within 7 days of filing 
and shall be similarly limited. 
(k) Requirements and sanctions. All briefs under this rule must be con-
cise, presented with accuracy, logically arranged with proper headings and 
free from burdensome, irrelevant, immaterial or scandalous matters. Briefs 
which are not in compliance may be disregarded or stricken, on motion or sua 
sponte by the court, and the court may assess attorney fees against the offend-
ing lawyer. 
(1) Brief covers. The covers of all briefs shall be of heavy cover stock and 
shall comply with Rule 27. 
(Amended effective October 1, 1992.) 
Advisory Committee Note. — The brief Amendment Notes. — The 1992 amend-
must now contain for each issue raised on ap- ment, effective October 1, 1992, added the 
peal, a statement of the applicable standard of third sentence in Subdivision (c) and made sty-
review and citation of supporting authority. iistic changes in Subdivisions (a)(5) and (7). 
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GENERAL BIOMETRICS, INC. 
BYLAWS 
OFFICES 
1. The corporation shall have ? registered office and 
maintain a registered agent i n tl le Sta tie Uaware. 
2. The corporation may also have offices at such 
other places as the board of directors may from time to time 
designate or the business of the corporat :i en ma\ req aire. 
SEAL 
3. The corporate seal shall have inscribed thereon 
the name of the corporation, the year of its organization and the 
words "Corporate Seal, Delaware"• 
•'> I'OCKHOLDER ' JJ MEET 1II ; 
4. All meetings of the stockholders shall be held at 
the office of the corporation, or at such place as may be fixed 
by the board of dir cified ... . of the 
meeting. 
The annual meeting of the stockholders, after the 
year 1978, shall be held or the last 
within HI u,i, iLiaieui. in each year, if ic;. JL legal holiday, and 
if a legal holiday, then on the next sec ilar day following, at 
2:00 p. they shall elect by a plurality vnfp l. of, 
to serve for one year and tiiiLii their* 
successors are elected or chosen and qualified. 
6. The holders of thirty-five (35%) percent of the 
stock issued and outstanding entitled to vote, present in person 
or represented by proxy, shall be requisite and shall constitute 
a quorum at all meetings of the stockholders for the transaction 
of business, except as otherwise provided by law, by the 
certificate of incorporation or by these bylaws. If, however, 
such majority shall nor be present or represented, the 
stockholders present in person, or by proxy shall have power to 
adjourn the meeting from time to time, without notice other than 
announcement at the meeting, until the requisite amount of stock 
shall be present. At such adjourned meering at which the 
requisite amount of stock shall be represented, any business may 
be transacted which might have been transacted at the meeting as 
originally notified. 
7. At each meeting of the stockholders, every 
stockholder having the right to vote shall be entitled to vote in 
person, or by proxy, appointed by an instrument in writing 
subscribed by such stockholder or by his duly authorized attorney 
and delivered to the inspectors at the meeting, and he shall have 
one vote for each share of stock having ' roting power, registered 
in his name on the books of the corporation. 
Except where the transfer books of the corporation 
shall have been closed or a date shall have been fixed as a 
record date for the determination of its stockholders entitled to 
vote, as hereinafter provided, no share of stock shall be voted 
on at any election for directors which hr.s been transferred on 
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the books of the corporation within twenty (20) days next 
preceding such election. 
8. Written notice of the annual meeting shall be 
mailed to each stockholder entitled to vote thereat, at such 
address as appears on the stock ledger of the corporation, at 
least ten (10) days prior to the meeting 
9. A complete list of the stockholders entitled to 
vote at the ensuing election, arranged in alphabetical order, 
with the residence of each, and the number of shares held bv 
each, shall be prepared and filed in the office where the 
election is to be held, at least ten (10> days before every 
election and shall, at all times, during the usual hours for 
business and during the whole time of sa. d election, be open to 
the examination of any stockholder. 
10. Special meetings of the sto c kh o ] d e r s , f ::) r a i i} -
purpost purposes, other than those reiulated by statute, may 
be called by the chief executive officer, and shall be called by 
the chief executive officer or secretary at the request i i I 
writing of a ma j on: i t; y i! !. "ie board of directors, or at the 
request in writing by stockholders owning a majority in amount of 
the entire capital stock of the corporation issued and 
outstanding and entitled ''ii,v luesi iiiuiij .bi.ate i.he 
purpose purposes of the proposed meeting, 
11. Business transacted at all special meetings shall 
be confined to the objects in the call and mntiters efeniune 
there ui. , 
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12. Written notice of a special meeting of 
stockholders, stating the time and place and object thereof shall 
be mailed, postage prepaid, at least ten (10) days before such 
meeting, to each stockholder entitled to vote thereat, at such 
address as appears on the books of the corporation. 
DIRECTORS 
13. The property and business of the corporation shall 
be managed by its board of directors which shall be at least 
three (3) but not more than nine (9) in rumber, as may from year 
to year be established by the board prior- to the annual meeting, 
and who need not be stockholders. They .shall be elected by the 
stockholders at the annual meeting of stockholders of the 
corporation, and each director shall be elected to serve for the 
term of one year, and until his successors shall be elected and 
qualified. Until further action is taken by the board the number 
of directors is 3, and any vacancies created by an increase in 
the number of directors may be filled by the directors for the 
term remaining before the next annual meeting of the 
stockholders. 
The directors shall elect a chairman of the board at 
each annual meeting. 
14. The directors may hold their meetings and have one 
or more offices and keep the books of the corporation, except the 
original or duplicate stock ledger, outside of Delaware, at such 
places as they may from time to time determine. 
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15. In addition to the powers and authority by these 
bylaws expressly conferred upon it, the board may exercise all 
such the corporation and do all such lawful acts and 
things as are not by statute or by the certificate of 
incorporation or by these bylaws directed or required to 
exercised or done by the stockholders. 
16. Without prejudice to the general powers conferred 
by the last preceding clause, and the other powers conferred by 
the statute, bv Mv* certificate of incorporation and by these 
bylaws, it is hereby expressly declared that the board of 
directors shall have the following powers, that is to say: 
(a) From time to time to make and change the 
rules and regulations not inconsistent with 
these bylaws, for the management of the 
corporation's business and affairs. 
(b) To purchase or otherwise acquire for the 
corporation any property, rights, or 
privileges which the corporation is 
authorized to acquire, at such price or 
consideration and generally on such terms 
conditions as they thing fit. 
(c) At their discretion to pay for any property 
or rights acquired by the corporation, either 
wholly or partly in money, stock, bonds 
debentures or other securities of the 
corporation. 
(d) i create, make and issue mortgages, bonds, 
deeds of trust, trust agreements ad 
negotiable or transferable instruments and 
securities, secured by mortgage or otherwise 
and to do every other act and thing necessary 
to effectuate the same. 
(e) To determine who shall be authorized on the 
corporation's behalf to sign bills, notes, 
receipts, acceptances, endorsements, checks, 
releases, contracts ..:nd documents. 
5 
(f) To delegate any of the powers of the board in 
the course of the current business of the 
corporation to any standing or special 
committee or to any officer or agent or to 
appoint any persons to be the agents of the 
corporation, with such powers (including the 
power to sub-delegate) and upon such terms as 
they think fit. 
MEETINGS OF THE BOARD 
17. The newly elected board may meet at such place and 
time as shall be fixed by the vote of the stockholders at the 
annual meeting for the purpose of organization and otherwise, and 
no notice of such meeting shall be necessary of the newly elected 
directors in order to legally constitute the meeting: PROVIDED a 
majority of the whole board shall be present; or such place and 
time may be fixed by the consent in writing of all the directors. 
18. Regular meetings of the board may be held without 
notice at the said time and place as shall from time to time be 
determined by the chairman or a majority of the other members of 
the board. 
19. At all meetings of the board a majority of the 
directors shall be necessary and sufficient to constitute a 
quorum for the transaction of business, and the act of a majority 
of the directors present at any meeting at which there is a 
quorum, shall be the act of the board of directors, except as may 
be otherwise specifically provided by statute or by the 
certificate of incorporation or by these bylaws. 
20. Special meetings of the board may be called by the 
chief executive officer on two (2) days' notice to each director, 
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either personally or my mail or by telegram; special meetings 
shall be called by the chief executive officer or secretary in 
like manner and on like notice '.he written request of two (2) 
directors. 
OFFICERS 
21. The officers of the corporation shall be the chief 
executive officer, a president or chief operating officer, one or 
more vice presidents, a secretary and a treasurer. Any two (2) 
of the aforesaid offices, except those or hi"! ^.etuLive officer 
and secreta be filled by the same person. 
22. The board of directors, at its first meeting after 
each annual meeting of the stockholders, sha chief 
executive officer, from their own number, and the board shall 
also annually choose a president, one or more vice presidents, a 
secretary and a treasurer who need not bo. members 
23. The board may appoint such other officers and 
agents as it shall deem necessary, who shall have such authority 
and shall perform such duties as from tine to time shall be 
prescribed by the board. 
24 . ries of all officers and agents of the 
corporation shall be fixed by the board of directors. 
25. The officers of the corporation sha] 3 1: i o] d office 
until their successors .ur chosen and qualified in their stead. 
officer elected or appointed by the board of directors may be 
removed at any time by the affirmative vr.te of a 
whole board of directors. 
GBI/061490/EEB 7 
EXECUTIVE COMMITTEE 
26. There may be an executive committee of two or more 
directors appointed by the board, who may meet at stated times, 
or on notice to all by any of their own number. During the 
intervals between the meetings of the board, they shall advise 
with and aid the officers of the corporation in all matters 
concerning its interests and the management of its business, and 
generally perform such duties and exercise such powers as may be 
directed or delegated by the board of directors from time to 
time. The board may delegate to such committee authority to 
exercise all the powers of the board, excepting power to amend 
the bylaws. Vacancies in the membership of the committee shall 
be filled by the board of directors at a regular meeting or at a 
special meeting called for that purpose. 
27. The executive committee snail keep regular minutes 
of its proceedings and report the same to the board when 
required. 
THE CHIEF EXECUTIVE OFFICER 
28. The chief executive officer shall direct and 
supervise the president and all other officers; he shall develop 
and implement the corporation's policies and procedures; he shall 
preside at all meetings of the stockholders and directors; he 
shall see that all orders and resolutions of the board are 
carried into effect, subject however, to the right of the 
directors to delegate any specific powers, except such as may be 
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by statute exclusively conferred on the chief executive officer, 
to any other officer or officers of the corporation. 
29. He shall execute bonds, mortgages other 
contracts requir ii :i j a seal, under the seal of the corporation; he 
shall keep in safe custody the seal of the corporation, and, when 
authorized by the board, affix the seal to any instrument 
requiring the samp, and the seal when so affixed shall be 
attested by the signature of the secretary or the treasurer. He 
or the president shall sign certificates of stock. 
30. He shall be i i .:>:-officio member of all standing 
committees. 
THE PREST DKMT . 
The president shall be the chief operating officer 
of the corporation; he shall direct the day-to-day business 
operations of the corporation c i i :i si rpex: i :i se the employees of the 
corporation; in the absence or disability of the chief executive 
officer, he shall perform the duties and exercise the powers of 
the chief executive officer; he shall i'«i 'Ti !\u:ates ol stock. 
VICE PRESIDENT 
32. The vice president shall, in the 
disability of the president, perform the duties and exercise the 
powers of the president, and shall perform such other duties as 
shall from time to time be imposed upon him by the board. In the 
event of there being more than MUM n H" pies uient, each vice 
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president shall have such duties as shall be assigned to him by 
the board of directors. 
THE SECRETARY 
33. The secretary shall attend all sessions of the 
board and all meetings of the stockholders and act as clerk 
thereof, and record all votes and the minutes of all proceedings 
in a book to be kept for that purpose; and shall perform like 
duties for the standing committees when required. He shall give, 
or cause to be given, notice of all meetings of the stockholders 
and of the board of directors, and shall perform such other 
duties as may be prescribed by the board of directors or chief 
executive officer under whose supervision he shall be. He may 
sign certificates of stock. He shall be sworn to the faithful 
charge of his duty. 
THE TREASURER 
34. The treasurer shall have the custody of the 
corporate funds and securities and shall keep full and accurate 
accounts of receipts and disbursements in books belonging to the 
corporation and shall deposit all money and other valuable 
effects in the name of and to the credit of the corporation, in 
such depositories as may be designated by the board of directors. 
35. He shall disburse the funds of the corporation as 
may be ordered by the board, taking proper vouchers for such 
disbursements and shall render to the chief executive officer and 
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directors, at the regular meetings of the board, or whenever they 
may require it, an account of all his transactions as treasurer 
and of the financial condition of the corporation. He may sign 
certificates of stock. 
36. He shall give the corporation a bond if required 
by the board of directors in a sum, and with one or more sureties 
satisfactory to the board, for the faithful performance of the 
duties of his office, and for the restoration to the corporation, 
in case of his death, resignation, retirement or removal from 
office, of all books, papers, vouchers, money and other property 
of whatever kind in his possession or under his control belonging 
to the corporation. 
VACANCIES 
37. If the office of any director, or of the chief 
executive officer, the president, vice president, secretary or 
other officer or agent, one or more, becomes vacant by reason of 
death, resignation, retirement, disqualification, removal from 
office, or otherwise, the directors then in office, although less 
than a quorum, by a majority vote, may choose a successor or 
successors who shall hold office for the unexpired term in 
respect of which such vacancy occurred. 
DUTIES OF OFFICERS MAY BE DELEGATED 
38. In case of the absence of any officer of the 
corporation or for any other reason that the board may deem 
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sufficient, the board may delegate the powers or duties of such 
officer to any other officer or to any director, for the time 
being, provided a majority of the entire board concur therein. 
CERTIFICATES OF STOCK 
39. The certificates of stock of the corporation shall 
be numbered and shall be entered in the books of the corporation 
as they are issued. They shall exhibit the holder's name and the 
number of shares and shall be signed by the chief executive 
officer or president or a vice president and treasurer or 
assistant treasurer or secretary or assistant secretary and shall 
bear the corporate seal. 
TRANSFERS OF STOCK 
40. Upon surrender to the corporation or the transfer 
agent of the corporation of a certificate for shares duly 
endorsed or accompanied by proper evidence of succession, 
assignment or authority to transfer, it ohall be the duty of the 
corporation to issue a new certificate to the person entitled 
thereto, cancel the old certificate and record the transaction 
upon its books. 
41. The corporation shall be entitled to treat the 
holder of record of any share or shares of stock as the holder in 
fact thereof, and accordingly shall not I>e bound to recognize any 
equitable or other claim to or interest in such share on the part 
of any other person, whether or not it s.'iall have express or 
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other notice thereof, save as expressly provided by the laws of 
Delaware. 
CLOSING OF TRANSFER BOOKS OR FIXING DATE FOR DETERMINATION 
OF STOCKHOLDERS OF RECORD FOR CERTAIN PURPOSES 
42. The board of directors shall have the power to 
close the stock transfer books of the corporation for a period 
not exceeding fifty (50) days preceding the date of any meeting 
of stockholders or the date for payment of any dividend or the 
date for the allotment of rights or the date when any change or 
conversion or exchange of capital stock shall go into effect; 
PROVIDED, however, that in lieu of closing the stock transfer 
books as aforesaid, the board of directors may fix in advance a 
date, not exceeding fifty(50) days preceding the date of any 
meeting of stockholders or the date for the payment of any 
dividend or the date for the allotment of rights, or the date 
when any change, or conversion or exchange of capital stock shall 
go into effect, as a record date for the determination of the 
stockholders entitled to notice of, and A,o vote at, any such 
meeting, or entitled to receive payment r.f any such dividend, or 
to any such allotment of rights, or to exercise the rights in 
respect of any such change, conversion o*- exchange of capital 
stock, and in such case only such stockholders as shall be 
stockholders of record on the date so fixed shall be entitled to 
such notice of, and to vote at, such meeting, or to receive 
payment of such dividend, or to receive such allotment of rights, 
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or to exercise such rights, as the case may be notwithstanding 
any transfer of any stock on the books of the corporation after 
any such record date fixed as aforesaid. 
LOST CERTIFICATE 
43. Any person claiming a certificate of stock to be 
lost, destroyed or stolen shall make an affidavit or affirmation 
of that fact and advertise the loss, if *.he board of directors 
shall so require, and shall give the corporation a bond of 
indemnity, in form and with one or more sureties satisfactory to 
the board, for an unspecified amount of an amount set by the 
board of directors, whereupon a new certificate may be issued of 
the same tenor and for the same number of shares as the one 
alleged to be lost, destroyed or stolen, but always subject to 
the approval of the board of directors. 
INSPECTION OF BOOKS 
44. The directors shall determine from time to time 
whether and, if allowed, when and under what conditions and 
regulations the accounts and books of the corporation,except such 
as may by statute be specifically open to inspection, or any of 
them shall be open to the inspection of the stockholders, and the 
stockholders rights in this respect are ^nd shall be restricted 
and limited accordingly. 
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CHECKS 
45. All checks or demands for money and notes of the 
corporation shall be signed by such officer or officers or agent 
as the board of directors may from time to time designate. 
46. The fiscal year shall be determined by the board 
of directors. 
DIVIDENDS 
47. Dividends upon the capital stock of the 
corporation, subject to the provisions of the certificate of 
incorporation, if any, may be declared by the board of directors 
at any regular or special meeting, pursuant to law. Dividends 
may be paid in cash, in property, or in shares of capital stock. 
48. Before payment of any dividend or making any 
distribution of profits, there shall be set aside out of the 
surplus or net profits of the corporation such sum or sums as the 
directors from time to time, in their absolute discretion, think 
proper as a reserve fund to meet contingencies, or for equalizing 
dividends or for repair or maintaining any property of the 
corporation, or for such other purposes as the directors shall 
think conducive to the interest of the corporation. 
DIRECTORS' ANNUAL STATEMENT 
49. The board of directors shall present at each 
annual meeting, and when called for by t.:e stockholders, at any 
special meeting of the stockholders, a full and clear statement 
of the business and condition of the corporation. 
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NOTICES 
50. Except as otherwise specifically provided herein 
or required by law, all notices required to be given to any 
stockholder, director, officer, employee or agent shall be in 
writing and may in every instance be effectively given by hand 
delivery to the recipient thereof, by depositing such notice in 
the mails, postage paid, or by sending s\.ch notice by prepaid 
telegram or mailgram. Any such notice shall be addressed to such 
stockholder, director, officer, employee or agent at his or her 
last known address as the same appears on the books of the 
corporation. The time when such notice is received by such 
stockholder, director, officer, employee or agent, or by any 
person accepting such notice on behalf of such person, if hand 
delivered, or dispatched, if delivered through the mails or by 
telegram or mailgram, shall be the time of the giving of the 
notice. 
AMENDMENTS 
51. The board of directors is expressly empowered to 
adopt, amend or repeal bylaws of the corporation. Any adoption, 
amendment or repeal of bylaws of the corporation by the board of 
directors shall require the approval of a majority of the total 
number of authorized directors (whether or not there exist any 
vacancies in previously authorized directorships at the time any 
resolution providing for adoption, amendment or repeal is 
presented to the board). The stockholders shall also have the 
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power to adopt, amend or repeal the bylaws of the corporation in 
the manner prescribed by the laws of the State of Delaware. 
INDEMNIFICATION OF DIRECTORS AND OFFICERS 
52. Each person who was or is made a party or is 
threatened to be made a party to or is involved in any action, 
suit or proceeding whether civil, criminal, administrative or 
investigative ("proceeding"), by reason of the fact that he or 
she or a person of whom he or she is the legal representative, is 
or was a director, officer or employee of the corporation or is 
or was serving at the request of the corporation as a director, 
officer or employee of another corporation, or of a partnership, 
joint venture, trust or other enterprise, including service with 
respect to employee benefit plans, whether the basis of such 
proceeding is alleged action in an official capacity as a 
director, officer or employee or in any other capacity while 
serving as a director, officer or employee, shall be indemnified 
and held harmless by the corporation to the fullest extent 
authorized by Delaware Law, as the same exists or may hereafter 
be amended (but, in the case of such amendment, only to the 
extent that such amendment permits the corporation to provide 
broader indemnification rights than said Law permitted to the 
corporation to provide prior to the amendment) against all 
expenses, liability and loss (including attorneys1 fees, 
judgments, fines, ERISA excise taxes or penalties, amounts paid 
or to be paid in settlement and amounts expended in seeking 
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indemnification granted to such person under applicable law, this 
bylaw or any agreement with the corporation) reasonably incurred 
or suffered by such person in connection therewith and such 
indemnification shall continue as to a person who has ceased to 
be a director, officer or employee and shall inure to the benefit 
of his or her heirs, executors and administrators; provided, 
however, that, except as provided in Section 2 of this paragraph, 
the corporation shall indemnify any such person seeking indemnity 
in connection with an action, suit or proceeding (or part 
thereof) initiated by such person only if such action, suit or 
proceeding (or part thereof) was authorized by the board of 
directors of the corporation. Such right shall be a contract 
right and shall include the right to be paid by the corporation 
expenses incurred in defending any such proceeding in advance of 
its final disposition; provided, however, that if the Delaware 
General Corporation Law then so requires, the payment of such 
expenses incurred by a director or officer of the corporation in 
his or her capacity as a director or officer (and not in any 
other capacity in which service was or is rendered by such person 
while a director of officer, including, without limitation, 
service to an employee benefit plan) in advance of the final 
disposition of such proceeding, shall be made only upon delivery 
to the corporation of an undertaking, by or on behalf of such 
director or officer, to repay all amounts so advanced if it 
should be determined ultimately that such director or officer is 
not entitled to be indemnified under this section or otherwise. 
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53. If a claim under paragraph 52 is not paid in full 
by the corporation with twenty (20) days after a written claim 
has been received by the corporation, the claimant may at any 
time thereafter bring suit against the corporation to recover the 
unpaid amount of the claim and, if such suit is not frivolous or 
brought in bad faith, the claimant shall be entitled to be paid 
also the expense of prosecuting such claim. It shall be a 
defense to any such action (other than an action brought to 
enforce a claim for expenses incurred in defending any proceeding 
in advance of its final disposition where the required 
undertaking, if any, has been tendered to this corporation) that 
the claimant has not met the standards of conduct which make it 
permissible under the Delaware General Corporation Law for the 
corporation to indemnify the claimant for the amount claimed, but 
the burden of proving such defense shall be on the corporation. 
Neither the failure of the corporation (including its board of 
directors, independent legal counsel, or its stockholders) to 
have made a determination prior to the commencement of such 
action that indemnification of the claimant is proper in the 
circumstances because he or she has met the applicable standard 
of conduct set forth in the Delaware General Corporation Law, nor 
an actual determination by the corporation (including its board 
of directors, independent legal counsel, or its stockholders) 
that the claimant has not met such applicable standard of 
conduct, shall be a defense to the action or create a presumption 
that claimant has not met the applicable standard of conduct. 
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54. The rights conferred on any person in paragraphs 
52 and 53 styall not be exclusive of any ether right which such 
persons may have or hereafter acquire under any statute, 
provision of the certificate of incorporation, bylaw, agreement, 
vote of stockholders or disinterested directors or otherwise. 
55. The board of directors is authorized to enter into 
a contract with any director, officer, employee or agent of the 
corporation, or any person serving at the request of the 
corporation as a director, officer, employee or agent of another 
corporation, partnership, joint venture, trust or other 
enterprise, including employee benefit p?ans, providing for 
indemnification rights equivalent to or, if the board of 
directors so determines, greater than, those provided for in 
these bylaws. 
56. Any amendment, repeal or modification of any 
provision of this section on indemnification by the stockholders 
and the directors of the corporation shall not adversely affect 
any right or protection of a director or officer of the 
corporation existing at the time of such amendment, repeal or 
modification. 
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MINUTES OF A SPECIAL MEETING 
OF THE BOARD OF DIRECTORS OF 
GENERAL BIOMETRICS, INC. 
NOVEMBER 30, 1989 
Pursuant to notice duly given, a Special Meering of the Board of 
Directors of General Biometrics, Inc. was held on Thursday, 
November 30, 1989 in the offices of Ventana Growth Fund. All 
members of the Board were present except for Robert A. Condie. 
Also present were Elaine E. Burroughs, Corporate Secretary; Craig 
E.R. Nichols, Corporate Controller; and Dan Dearen of Ventana 
Growth Fund. 
Mr. Townsen, Chairman of the Board, called the meeting to order at 
4:15 p.m. 
The first order of business was a report by Mr. Gordy on the status 
of the Company's current private offering relating to the sale of 
up to $3 million of Limited Partnership interests. Mr. Gordy 
reported that the private placement memorandum had been completed 
and that a selling effort by the Placement Agent had begun. 
The next order of business was a discussion of the Company's 
current financial status with an emphasis being placed on 
establishing a "critical mass11 budget and management of cash flow. 
Thereafter, a discussion was had concerning the- possibilities of 
selling the Company's MRC division. It was the sense of the Board 
that Mr. Gordy should investigate the possible sale of this 
division and should bring any potential offers to the Board for 
further discussion and decision. 
Thereupon a discussion was had concerning the vesting requirements 
with respect to certain of the Incentive Stock Options previously 
granted to key employees, taking into account the fact that certain 
of the vesting terms thereunder now appeared to be impractical. 
Following discussion, the following resolution was made, seconded, 
and unanimously passed: 
RESOLVED that the vesting terms with respect 
to the Options shown on Exhibit A, a copy of 
which shall be attached to and made a part of 
these minutes, shall be amended so that hence-
forth with respect to these Options, 50% thereof 
shall vest at such time as the Company shall 
have six (6) consecutive months of profitability 
and 50% of said Options shall vest at such time 
as the Company shall have six (6) consecutive 
months of positive cash flow. 
A discussion was then had with respect to executive compensation. 
The following resolution was thereupon made, seconded, and passed 
with Mr. Gordy abstaining from the vote: 
RESOLVED, that the Board of Directors hereby 
approves an increase in salary for John T. Gordy 
to $110,000 per annum effective December 1, 1989. 
A discussion was then held concerning the necessity for retaining 
key employees during this critical period for the Company. The 
following resolution was thereupon made, seconded, and unanimously-
passed: 
RESOLVED that the Board of Directors approves 
and directs John T. Gordy to offer Incentive 
Stock Options from the available ISO pool to 
employees who are considered "Key11 to the success 
of the Company. 
A discussion was then held concerning certain promissory notes 
aggregating $1,847,000 executed by the Company in favor of Ventana 
Growth Fund and Ventana Growth Fund II. A schedule of said notes 
is attached hereto as Exhibit B. Following discussion thereof the 
following resolutions were made, seconded and unanimously passed: 
RESOLVED, that the execution and delivery of 
the promissory notes set forth on Exhibit B 
hereto, are hereby ratified, adopted and 
approved as and for acts of this Corporation. 
RESOLVED, FURTHER, that the Corporation 
authorizes, subject to the approval of Ventana 
Growth Fund and Ventana Growth Fund II, to 
amend each of said notes (1) by amending 
Paragraph 3 (1) thereof to extend the date 
set forth therein from December 31, 1989 to 
March 31, 1991 and (2) by providing 
for interest to be payable thereon quarterly. 
RESOLVED, FURTHER, that the officers of the 
Corporation and each of them are hereby 
authorized and directed on behalf of the 
Corporation and in its name, to take all 
further actions and execute all further 
documents necessary or desirable in order 
to carry out the purpose and intent of the 
aforesaid resolutions. 
A discussion was then held concerning capitalizing certain software 
development costs of the Company's DataGene Scientific 
Laboratories, Inc. subsidiary. Following discussion, the following 
resolution was made, seconded and unanimously passed: 
WHEREAS, DataGene Scientific Laboratories, 
Inc., ("DataGene") the Company's wholly-owned 
subsidiary, carries on its balance sheet (and 
thereby in the Company's consolidated financial 
statements) capitalized software development 
costs in amounts totaling $462,923.57 from 
prior fiscal years; and 
WHEREAS, these costs were capitalized when 
DataGene was actively developing the Inheritel 
product for sale; and 
WHEREAS, DataGene is now and has been for 
the last year a dormant Corporation without 
the facilities or the funds to proceed with the 
development, production and marketing of the 
Inheritel product, nor does it anticipate the 
ability to do so in the foreseeable future; 
NOW, THEREFORE, BE IT RESOLVED, that the 
Controller of the Company be instructed to 
expense the entire $462,923.57 in software 
development costs as at September 30, 1989. 
A discussion was then held concerning the increased time and 
attention required by the Company from Ventana Growth Fund. 
Following discussion, the following resolution was made, seconded 
and unanimously passed : 
WHEREAS, the Company has recently required 
time and attention from Ventana Growth Funds 
and in particular, Mr. F. Duwaine Townsen, over 
and above that routinely required. 
BE IT, THEREFORE, RESOLVED, that the Board of 
Directors authorizes and directs John T. Gordy 
to enter into a Consulting Agreement with Ventana 
Growth Funds on behalf of the Company, whereby the 
Company will pay Ventana Growth Funds for consult-
ing services at the rate of $2,000 per month 
retroactively from May 1989 until January 1990. 
There being no further business for discussion, the meeting was 
duly adjourned at 7:00 p.m. 
Respectfully submitted, 
Elaine E. Burroughs ^ ^ 
Corporate Secretary 
GENERAL BIOMETRICS, INC. 
BOARD OF DIRECTORS MEETING 
NOVEMBER 30, 1989 
EXHIBIT A 
U OF 
tMPLOYEE SHARES PRICE 
ADLER, FRED 
ANDERSON, MICHAEL 
BURROUGHS, ELAINE 
DONOVAN, KERRY 
FRANEY, CONNIE 
GOLEK, AUDREY 
ISAKSEN, JOHN 
kESSLER, RALPH 
NICHOLS, CRAIG 
SHbALY, DAVID 
VAUGHAN, KENUARD 
40,000 
5,000 
7,500 
7,500 
7,500 
5,000 
10,000 
7,500 
15,000 
5,000 
7,500 
0.7500 
0.5625 
0.5625 
0.2000 
0.1250 
0.1250 
0.3125 
0.1250 
0.8/50 
0.1250 
0.1250 
TOTAL: 117,500 
OPTIONS GRANTED WITH FOUR POINT VESTING SCHEDULE 
GENERAL BIOMETRICS, INC, 
BRIDGE LOANS 
EXHIBIT B 
NUMBER 
1 
2 . 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
DATE OF NOTE 
7-15-88 
7-26-88 
8-2-88 
10-3-88 
10-14-88 
10-16-88 
11-1-88 
11-15-88 
11-23-88 
12-7-88 
12-23-88 
1-3-89 
1-17-89 
2-1-89 
2-6-89 
2-10-89 
3-3-89 
AMOUNT OF NOTE 
$ 112,000 
27,000 
50,000 
135,000 
50,000 
165,000 
170,000 
116,000 
172,000 
100,000 
75,000 
25,000 
100,000 
125,000 
150,000 
125,000 
150,000 
TOTAL 1 ,847 ,000 
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PROMISSORY NOTE 
$ 1 1 2 , 0 0 0 , 0 0 S a n D i e g o , C a l i f o r n i a 
J u l y 1 5 , 1 9 8 8 
!• OBLIGATION- GENERAL BIOMETRICS, INC., ("Maker"), 11199 
Sorrento Valley Road, Suite A, San Diego, California 92121, for 
value received, hereby promises to pay to VENTANA GROWTH FUND 
("Holder"), at 1660 Hotel Circle North, Suite 730, San Diego, 
California 92108, the principal amount of ONE HUNDRED TWELVE 
THOUSAND DOLLARS ($112,000). 
2. 1NTEBKQT_JIAT£. Maker further promise* to pay to the 
Holder hereof interest on the outstanding principal balance of 
this Note at the rate of 9*00% per annum, payable semi-annually. 
3. TERM. Tho principal amount of this Note and all 
accrued interest becomes due and payable on (1) December 31, 
1989, or (2) sixty (60) days following the closing of a major 
private or public General Biometrics financing of $3,000,000,-
whichever comes first. 
4. OTHER. As approved by the General Biometrics Board of 
Directors, Maker will cause Warrants to be issued fcr 28,000 
shares of Maker's common stock. The Warrant price is $1.00 per 
share and the expiration date is July 14, 1991. 
5. AUTHORITY. The undersigned individual signing this 
Note represents and warrants that he is the President of General 
Biometrics and has been authorized and empowered by the Board of 
Directors to execute and deliver this Note on behalf of Maker. 
GENERAL BIOMETRICS, INC. 
/-Jbhri T. Gordy, President 
July 15, 1988 
(' \ 
PROMISSORY NOTE 
$ 2 7 , 0 0 0 , 0 0 San D i e g o , C a l i f o r n i a 
J u l y 2 6 , 1988 
1. OBLIGATION. GENERAL BIOMETRICS, I N C , ("Maker"), 11199 
Sorrento Valley Road, Suite A, San Diego, California 92121, for 
value received, hereby promises to pay to VENTANA GROWTH FUND 
("Holder"), at 1660 Hotel Circle North, Suite 730, San Diego, 
California 92108, the principal amount of TWENTY-SEVEN THOUSAND 
DOLLARS ($27,000). 
2. INTEREST RATE. Maker further promises to pay to the 
Holder hereof interest on the outstanding principal balance of 
this Note at the rate of 9.00% per annum, payable semi-annually. 
3. TERM. The principal amount of this Note and all 
accrued interest becomes due and payable on (1) December 31, 
1989, or (2) sixty (60) days following the closing of a major 
private or public General Biometrics financing of $3,000,000,-
whichever comes first. 
4. OTHER. As approved by the General Biometrics Board of 
Directors, Maker will cause Warrants to be issued for 6,750 
shares of Maker's common stock. The Warrant price is $1.00 per 
share and the expiration date is July 25, 1991. 
5. AUTHORITY. The undersigned individual signing this 
Note represents and warrants that he is the President of General 
Biometrics and has been authorized and empowered by the Board of 
Directors to execute and deliver this Note on behalf of Maker. 
GENERAL BIOMETRICS, INC, 
<-~-~"U~bhn T. Gordy, President 
July 26, 1988 
PROMISSORY NOTE 
$50,000.00 San Diego, California 
August 2, 1988 
1. PPLISATIQli. GENERAL BIOMETRICS, INC., ("Maker"), 11199 
Sorrento Valley Road, Suite A, San Diego, California 92121, for 
value received, hereby promises to pay to VENTANA GROWTH FUND 
("Holder"), at 1660 Hotel Circle North, Suite 730, San Diego, 
California 92108, the principal amount of FIFTY THOUSAND DOLLARS 
($50,000)• 
2- INTEREST RATff. Maker further promises to pay to the 
Holder hereof interest on the outstanding principal balance of 
this Note at the rate of 9.00% per annum, payable semi-annually. 
3. TERM. The principal amount of this Note and all 
accrued interest becomes due and payable on (1) December 31, 
1989, or (2) sixty (60) days following the closing of a major 
private or public General Biometrics financing of $3,000,000,-
whichever comes first. 
4. OTHER. As approved by the General Biometrics Board of 
Directors, Maker will cause Warrants to be issued for 12,500 
shares of Maker's common stock. The Warrant price is $1.00 per 
share and the expiration date .is August 1, 1991. 
5. AUTHORITY. The undersigned individual signing this 
Note represents and warrants that he is the President of (General 
Biometrics and has been authorized and empowered by the Board of 
Directors to execute and deliver this Note on behalf of Maker. 
GENERAL BIOMETRICS, INC. 
T. Gordy, PrdB^dent: 
August 2, 1988 
JPcJhn 
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PROMISSORY NOTE 
$135,000.00 San Diego, California 
October 3, 1988 
1. OBLIGATION, GENERAL BIOMETRICS, INC., ("Maker"), 11199 
Sorrento Valley Road, Suite A, San Diego, California 92121, for 
value received, hereby promises to pay to VENTANA GROWTH FUND 
("Holder"), at 1660 Hotel Circle North, Suite 730, San Diego, 
California 92108, the principal amount of ONE HUNDRED THIRTY-FIVE 
THOUSAND DOLLARS ($135,000). 
2. INTEREST RATE. Maker further promises to pay to the 
Holder hereof interest on the outstanding principal balance of 
this Note at the rate of 9.00% per annum, payable semi-annually, 
3. TEEM* The principal amount of this Note and all 
accrued interest becomes due and payable on (1) December 31, 
1989, or (2) sixty (60) days following the closing of a major 
private or public General Biometrics financing or $3,000,000,-
whichever comes first. 
4# OTHER. As approved by*the General Biometrics Board of 
Directors, Maker will cause Warrants to be issued for 67,500 
shares of Maker1s common stock. The Warrant price is $0,125 per 
share and the expiration date is October 2, 1991. 
5. AUTHORITY. The undersigned individual signing this 
Note represents and warrants that he is the President of General 
Biometrics and has been authorized and empowered by the Board of 
Directors to execute and deliver this Note on behalf of Maker. 
GENERAL BIOMETRICS, INC. 
jc^rfTT. Cordy, President v ^ 
October 3, 1988 
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PROMISSORY NOTE 
$50,000.00 San Diego, California 
October 14, 1938 
1. OBLIGATION. GENERAL BIOMETRICS, INC., ("Maker") , 11199 
Sorrento Valley Road, Suite A, San Diego, California 92121, for 
value received, hereby promises to pay to VENTANA GROWTH • FUND 
("Holder"^ at 1660 Hotel Circle North, Suite 730, San Diego, 
California 92108, the principal amount of FIFTY THOUSAND DOLLARS 
($50,000). 
2. INTEREST RATE. Maker further promises to pay to the 
Holder hereof interest on the outstanding principal balance of 
this Note at the rate of 9.00% per annum, payable semi-annually. 
3. TERM. The principal amount of this Note and all 
accrued interest becomes due and payable on (1) December 31, 
1989, or (2) sixty (60) days following the closing of a major 
private or public General Biometrics financing of $3,000,000,-
whichever comes first. 
4. OTHER. As approved by the General Biometrics Board of 
Directors, Maker will cause Warrants to be issued for 25,000 
shares of Maker's common stock. The Warrant price is $0,125 per 
share and the expiration date is October 13, 1991. 
5. AUTHORITY. The undersigned individual signing rhis 
Note represents and warrants that he is the President of General 
Biometrics and has been authorized and empowered by the Board of 
Directors to execute and deliver this Note on behalf of Maker. 
GENERAL BIOMETRICS, INC. 
John T. Gordy, President1 
October 13, 1988 
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PROMISSORY NOTE 
$165,000*00 San Diego, California 
October 16, 1988 
1. OBLIGATION. GENERAL BIOMETRICS, INC., ("Maker"), 11199 
Sorrento Valley Road, Suite A, San Diego, California 92121, for 
value received, hereby promises to pay to VENTANA GROWTH' FUND 
("Holder0), at 1660 Hotel Circle North, Suite 730, San Diego, 
California 92108, the principal amount of ONE HUNDRED SIXTY-FIVE 
THOUSAND DOLLARS ($165,000). 
2. INTEREST RATE. Maker further promises to pay to the 
Holder hereof interest on the outstanding principal balance of 
this Note at the rate of 9.00% per annum, payable semi-annually, 
3- TERJM. The principal amount of this Note and all 
accrued Interest becomes due and payable on (1) December 31, 
1989, or (2) sixty (60) days following the closing of a major 
private or public General Biometrics financing of $3,000,000,-
whichever comes first• 
4. OTHL'K* As approved by the General Biometrics Board of 
Directors, Maker will cause Warrants to be issued for 82,500 
shares of Makor'e common stock. The Warrant price is $0,125 per 
share and the expiration date is October 15, 1991. 
5. AUTHORITY. The undersigned individual signing this 
Note represents and warrants that he is the President of General 
Biometrics and has been authorized and empowered by the Board of 
Directors to execute and deliver this Note on behalf of Maker. 
GENERAL BIOMETRICS, INC, 
October 16, 1988 
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PROMISSORY NOTE 
$170,000.00 San Diego, California 
November 1, 1988 
1* OBLIGATION, GENERAL BIOMETRICS, I N C , ("Maker"), 11199 
Sorrento Valley Road, Suite A, San Diego, California 92121, for 
value received, hereby promises to pay to VENTANA GROWTH FUND 
("Holder"), at 1660 Hotel Circle North, Suite 730, San Diego, 
California 92108, the principal amount of ONE HUNDRED SEVENTY 
THOUSAND DOLLARS ($170,000). 
2. INTEREST RATE, Maker further promises to pay to the 
Holder hereof interest on the outstanding principal balance of 
this Note at the rate of 9.00% per annum, payable semi-annually. 
3. TERM. The principal amount of this Note and all 
accrued interest becomas due and payable on (1) December 31, 
1989, or (2) sixty (60) days following the closing of a major 
private or public General Biometrics financing of $3,000,000,-
whichever cornea first. 
4. <2323B- As approved by the General Biometrics Board of 
Directors, Maker will cause Warrants to be Issued for 85,000 
shares of Maker's common stock. The Warrant price is $0,125 per 
share and the axpiration data is October 31, 1991. 
5. AUTHORITY- The undersigned individual signing this 
Note represents and warrants that he is the President of Ganeral 
Biometrics and has been authorized and empowered by the Board of 
Directors to execute and deliver this Note on behalf of Maker. 
GENERAL BIOMETRICS, INC. 
John T. Gordy, President. 
November 1, 1988 
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PROMISSORY NOTE 
$116,000.00 San Diego, California 
November 15, 1988 
1- OBLIGATION. GENERAL BIOMETRICS, INC. , ("Maker"), 11199 
Sorrento Valley Road, Suite A, San Diego, California 92121, for 
value received, hereby promises to pay to VENTANA GROWTH FUND II 
("Holder"), at 1660 Hotel Circle North, Suite 730, San Diego, 
California 92108, the principal amount of ONE HUNDRED SIXTEEN 
THOUSAND DOLLARS ($116,000). 
2. INTEREST RATE. Maker further promises to pay to the 
Holder hereof interest on the outstanding principal balance of 
this Note at the rata of 9.00% per annum, payable semi-annually. 
3. XBBH» The principal amount of this Nota and all 
accrued interest becomes due and payable on (1) December 31, 
1989, or (2) sixty (60) days following the closing of a major 
private or public General Biometrics financing of $3,000,000,-
whichever comes first, 
4. QTBER- As approved by the General Biometrics Board of 
Directors, Maker will cause Warrants to be issued for 58,000 
shares of Maker's common stock. The Warrant price is $0*125 per 
share and the expiration date is November 14, 1991. 
5. AUTHORITY. The undersigned individual signing this 
Note represents and warrants that he is the President of General 
Biometrics and has been authorized and empowered by the Board of 
Directors to execute and deliver this Note on behalf of Maker. 
GENERAL BIOMETRICS, INC. 
Jo£n T. Gordy, Pr^orident 
November 15, 1988 
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PROMISSORY NOTE 
$172,000.00 sun Diego, California 
November 23, 1988 
1. OBLIGATION, GENERAL BIOMETRICS, INC, , ("Maker"), 11199 
Sorrento Valley Road, Suite A, San Diego, California 92121, for 
value racelved, hereby promises to pay to VENTANA GROWTH FUND II 
("Holder11), at 1660 Hotel Circle North, Suite 730, San Diego, 
California 92108, the principal amount of ONE HUNDRED SEVENTH-TWO 
THOUSAND DOLLARS ($172,000). 
2. INTEREST RATE. Maker further promises to pay to the 
Holder hereof Interest on the outstanding principal balance of 
this Note at the rate of 9-00% per annum, payable semi-annually. 
3. TERM. The principal amount of this Note and all 
accrued interest becomes due and payable on (1) December 31, 
1989, or (2) sixty (60) days following the closing of a major 
private or public General Biometrics financing of $3,000,000,-
whichever comes first:. 
4. QT11EK. As approved by the General Biometrics Board of 
Directors, Maker will cause Warrants to be issued for 86,000 
shares of Maker's common stock. The Warrant price is $0,125 per 
share and the expiration date is November 22, 1991. 
5. AUTHORITY. The undersigned individual signing this 
Note represents and warrants that he is the President of General 
Biometrics and has been authorized and empowered by the Board of 
Directors to execute and deliver this Note on behalf of Maker.. 
GENERAL BIOMETRICS, INC. 
John T. Gordy, r^-aetident 
vember 23, 1988 
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PROMISSORY NOTE 
$100,000.00 San Diego, California 
December 7, 1988 
1. OBLIGATION. GENERAL BIOMETRICS, INC, ("Maker"), 11199 
Sorrento Valley Road, Suite A, San Diego, California 92121, for 
value received, hereby promises to pay to VENTANA GROWTH FUND II 
("Holder"), at 1660 Hotel Circle North, Suite 730, San Diego, 
California 92108, the principal amount of ONE HUNDRED THOUSAND 
DOLLARS ($100,000). 
2. INTEREST RATE, Maker further promises to pay to the 
Holder hereof interest on the outstanding principal balance of 
this Note at the rate of 9.00% per annum, payable semi-annually. 
3. TERM. The principal amount of this Note and all 
accrued interest• becomes due and payable on (1) December 31, 
1989, or (2) sixty (60) days following the closing of a major 
private or public General Biometrics financing of $3,000,000,-
whichever comes first. 
4. OTHER. As approved by the General Biometrics Board of 
Directors, Maker will causa Warrants to be issued for 50,000 
shares of Maker's common stock. The Warrant price is $0,125 per 
share and the expiration date is December 6, 1991. 
5. AUTHORITY. The undersigned individual signing this 
Note represents and warrants that he is the President of General 
Biometrics and has been authorized and empowered by the Board of 
Directors to execute and deliver this Note on behalf of Maker, 
GENERAL BIOMETRICS, INC. 
December 8, 1988 
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PROMISSORY NOTE 
$125,000.00 San Diego, California 
February io, 1989 
!• PPLI<?ftTION. GENERAL BIOMETRICS, INC., ("Maker"), 11199 
Sorrento Valley Road, Suite A, San Diego, California 92121, for 
value received, hereby promises to pay to VENTANA GROWTH FUND I I 
("Holder"), at 1660 Hotel Circle North, Suite 730, San Diego, 
California 92108, the principal amount of ONE HUNDRED TWENTY-FIVE 
THOUSAND DOLLARS ($125,000). 
2. INTEREST RATE, Maker further promises to pay to the 
Holder hereof interest on the outstanding principal balance of 
this Note at the rate of 9.00% per annum, payable semi-annually. 
3. TERM. The principal amount of this Note and all 
accrued interest becomes due and payable on (1) December 31, 
1989, or (2) sixty (60) days following rhe closing of a major 
private or public General Biometrics financing of $3,000,000,-
whichever comes first. 
4. OTHER. As approved by the General Biometrics Board of 
Directors, Maker will cause Warrants to be Issued for 62,500 
shares of Maker*s common stock. The Warrant price i3 $0,125 per 
share and the expiration date is February 9, 1992. 
5. AUTHORITY. The undersigned individual signing this 
Note represents and warrants that he is the President of Gereral 
Biometrics and has been authorized and empowered by the Board of 
Directors to execute and deliver this Note on behalf of Maker. 
GENERAL BIOMETRICS, INC-
February 10, 1989 
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PROMISSORY NOTE 
$75,000.00 San Diego, California 
December 23, 1988 
1- OBLIGATION. GENERAL BIOMETRICS, INC., ("Maker"), 11199 
Sorrento Valley Road, Suite A, San Diego, California 92121, for 
value received, hereby promises to pay to VENTANA GROWTH FUND II 
("Holder"), at 1660 Hotel Circle North, Suite 730, San Diego, 
California 92108, the principal amount of SEVENTH-FIVE THOUSAND 
DOLLARS ($75,000). 
2. INTEREST RATE. Maker further promises to pay to the 
Holder hereof Interest on the outstanding principal balance of 
this Note at the rate of 9.00% per annum, payable semi-annually. 
3. TERM. The principal amount of this Note and all 
accrued interest: becomes due and payable on (1) December 31, 
1989, or (2) sixty (60) days following the closing of a major 
private or public General Biometrics financing of $3,000,000,-
whichever comes first. 
4. QTHJb'K* As approved by the General Biometrics Board of 
Directors, Maker will cause Warrants to be issued for 37,500 
shares of Maker's common stock. The Warrant price is $0,125 per 
share and the expiration date is December 22, 1991. 
5. AUTHORITY. The undersigned individual signing this 
Note represents and warrants that he is the President of General 
Biometrics and has been authorized and empowered by the Board of 
Directors to execute and deliver this Note on behalf of Maker. 
GENERAL BIOMETRICS, INC. 
John T. Gordy, President. 
\ 
ecember 23, 1988 
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PROMISSORY NOTE 
$25,000*00 San Diego, California 
January 3, 1989 
1. OBLIGATION, GENERAL BIOMETRICS, INC, , ("Maker"), 11199 
Sorrento Valley Road, Suite A, San Diego, California 92121, ror 
value received, hereby promises to pay to VENTANA GROWTH FUND II 
("Holder"), at 1660 Hotel Circle North, Suita 730, San Diego, 
California 92108, the principal amount of TWENTY-FIVE THOUSAND 
DOLLARS ($25,000). 
2. INTEREST RATE, Maker further promises to pay to the 
Holder her.eof interest on the outstanding principal balance, of 
this Note at tho rate of 9.00% per annum, payable semi-annually• 
3. XSEM« The principal amount of this Note and all 
accrued interest becomes due and payable on (1) December 31, 
1989, or (2) sixty (60) days following the closing of a major 
private or public General Biometrics financing of $3,000,000,-
whichever comos first. 
4. OTHEB, As approved by the General Biometrlca Board of 
Directors, Maker will cause Warrants to be Issued for 12,500 
shares of Maker's common stock* The Warrant price is $0*125 per 
share and the expiration data is January 2, 1992. 
5. AUTHORITY. The undersigned Individual signing this 
Note represents and warrants that he is the President of General 
Biometrics and has been authorized and empowered by the Board of 
Directors to execute and deliver this Note on behalf of Maker. 
GENERAL BIOMETRICS, INC. 
-~-S5> 
John T. Gordy, Pre^ -idfest; 
January 3, 1989 
/ 
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PROMISSORY NOTE 
$100,000.00 San Diego, California 
January 17, 1989 
1. PBLI5ATIPN* GENERAL BIOMETRICS, INC., ("Maker"), 11199 
Sorrento Valley Road, Suite A, San Diego, California 92121, for 
value received, hereby promises to pay to VKNTANA GROWTH FUND II 
("Holder"), at 1660 Hotel Circle North, Suite 730, San Diego, 
California 92108, the principal amount of ONE HUNDRED THOUSAND 
DOLLARS ($100,000). 
2« INTEREST RATE. Maker further promises to pay to the 
Holder hereof interest on the outstanding principal balance of 
this Note at the rate of 9.00% per annum, payable semi-annually* 
3. XEBM. The principal amount of this Note and all 
accrued interest becomes due and payable on (1) Dacember 31, 
1989, or (2) sixty (60) days following the closing of a major 
private or public? General Biometrics financing of $3,000,000,-
whichever comes first. 
4. <2XHEB« As approved by the General Biometrics Board of 
Directors, Maker will cause Warrants to be issued for 50,000 
shares of Maker's common stock. The Warrant price is $0*125 per 
share and the expiration date is January 16, 1992. 
5. AUTHORITY. The undersigned individual signing this 
Note represents and warrants that he is the President of General 
Biometrics and has been authorized and empowered by the Board of 
Directors to execute and deliver this Note on behalf of Maker. 
GENERAL BIOMETRICS, INC. 
January 18, 1989 
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PROMISSORY NOTE 
$125,000.00 San Diego, California 
February l, 1989 
1. OBLIGATION. GENERAL BIOMETRICS, INC., ("Maker"), 11199 
Sorrento Valley Road, Suite A, San Diego, California 92121, for 
value received, hereby promises to pay to VENTANA GROWTH FUND II 
("Holder11), at 1660 Hotel Circle North, Suite 730, San Diego, 
California 92108, the principal amount of ONE HUNDRED TWENTY-FIVE 
THOUSAND DOLLARS ($125,000). 
2. INTEREST RATE. Maker further promises to pay to* the 
Holder hereof interest on the outstanding principal balance of 
this Note at the rate of 9.00% per annum, payable semi-annually. 
3. TERM. The principal amount of this Note and all 
accrued interest becomes due and payable on (1) December 3 1, 
1989, or (2) sixty (60) days following the closing of a major 
private or public General Biometrics financing of $3,000,000,-
whichever comes first. 
4. OTHER. As approved by the General Biometrics Board of 
Directors, Maker will cause Warrants to be issued for 62,500 
shares of Maker1s common stock. The Warrant price is $0,125 per 
share and the expiration date is January 31, 1992. 
5. AUTHORITY. The undersigned individual signing this 
Note represents and warrants that he is the President of General 
Biometrics and has been authorized and empowered by the Board of 
Directors to execute and deliver this Note on bahalf of Maker. 
GENERAL BIOMETRICS, INC. 
hn T 7 Gordy, PrffBrittent 
February 7, 1989 
<3 
PROMISSORY NOTE 
$150,000.00 San Diego, California 
February 6, 1909 
1. OBLIGATION. GENERAL BIOMETRICS, INC., ("Maker"), 11199 
Sorrento Valley Road, Suite A, San Diego, California 92121, for 
value received, hereby promises to pay to VENTANA GROWTH FUND II 
("Holder"), at 1660 Hotel Circle North, Suite 730, San Diego, 
California 92108, the principal amount of ONE HUNDRED FIFTY 
THOUSAND DOLLARS ($150,000). 
2. INTEREST RATE. Maker further promises to pay to- the 
Holder hereor interest on the outstanding principal balance of 
this Note at the rate of 9.00% per annum, payable semi-annually. 
3. XEfiH* The principal amount of this Note and all 
accrued interest becomes due and payable on (1) December 21, 
1989, or (2) sixty (60) days following the closing of a major 
private or public General Biometrics financing of $3,000,000,-
whichever comes first. 
4. OTHER. As approved by the General Biometrics Board of 
Directors, Maker will causa Warrants to be Issued for 75,000 
chares of Maker's common stock. The Warrant price is $0,125 per 
share and the expiration date is February 5, 1992. 
5. AUTHORITY. The undersigned individual signing this 
Note represents and warrants that he is the President of General 
Biometrics and has been authorized and empowered by the Board of 
Directors to execute and deliver this Note on behalf of Maker. 
GENERAL BIOMETRICS, INC. 
February 7, 1989 
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PROMISSORY HOTS 
§150,000,00 San Diego, California 
March 3, 1989 
1. OPfrJQATIQN. GENERAL BIOMETRICS, INC., ("Maker"), 11199 
Sorrento Valley Road, Suite A, San Diego, California 92121, for 
hereby promises to pay to VENTANA GROWTH FUND II 
1660 Hotel circle North, Suit* 730, San Diego, 
California 92108, the principal amount of ONE HUNDRED FIFTY 
THOUSAND DOLLARS ($150,000). 
value received, 
("Holder"), at 
2, INTEREST RATE* Maker further promises to pay to the 
Holder hereof interest on the outstanding principal balance of 
thitt Note at the rate of 9*00% per annum, payable semi-annually. 
3. i£jJH. The principal amount of this Note and all 
accrued interest become* due and payable on (1) December 31, 
1989, or (2) sixty (60) days following the closing of a major 
private or public General Biometrics financing of $3,000,000,-
whichever comes first. 
4* OTHER« As approved by the General Biometrics Board of 
Directors, Maker will cause Warrants to be issued for 75,000 
shares of Maker's common stock. The Warrant price is $0,125 per 
share and the expiration date is March 2, 1992. 
5. AUTHORITY. The undersigned individual signing this 
Note represents and warrants that he is the President of General 
Biometrics and has been authorized and empowered by the Board of 
Directors to execute and deliver"this Note on behalf of Maker. 
GENERAL BIOMETRICS, INC. 
PresTdSntT 
March 3, 1989 
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ADDENDUM TO THE 
MINUTES OF A SPECIAL MEETING 
OF THE BOARD OF DIRECTORS OF 
GENERAL BIOMETRICS, INC, 
November 30, 1989 
This Addendum is to be attached to and be considered a part of the 
Minutes of the meeting of the 3oard of Directors of General 
Biometrics, Inc., held on November 30, 19.89. The following items 
were discussed and resolved by Directors F. Duwaine Townsen, 
Chairman, James R. Yarter and John T. Gordy during said meeting in 
the absence of the Corporate Secretary. 
RESOLVED, that the annual salary of John T, Gordy, 
President and CEO of the Company, be raised to $135,000/year 
when the Company has shown a profit and a positive cash flow 
for three (3) consecutive months as determined by the 
Company's Controller. 
RESOLVED, that John T. Gordy be granted Incentive Stock 
Options (from the Company's ISO pool) for Fifty Thousand 
(50,000) shares. These options are for a three-year period at 
the fair market value on November 30, 1989 ($0 • 625/share) and 
vest immediately. 
RESOLVED, that, in the event of the sale of the Company's 
Utah division (MRC) , John T. Gordy will be remunerated for his 
efforts on the Company's behalf according to the following 
schedule: 
MRC is sold for less than $500,000; no remuneration. 
MRC is sold for $500,000 or greater; Mr. Gordy 
receives five (5%) percent of the net sale amount 
up to a maximum of Fifty Thousand ($50,000) 
Dollars. 
RESOLVED, that Ventana Growth Funds, present holder c _ 
1,261,250 warrants to purchase the Company's common stock a^ 
$0 .125/share, agrees to transfer 5_0V000 of these warrants into 
the name of John T. Gordy upon his achievement of certain 
performance goals to the satisfaction of the Board of 
Directors. These goals are to be defined and placed on the 
Corporate record by the Board of Directors. 
This Addendum is hereby attested to on this <^X^ day of March 1990. 
:/ ' 
- - / / - - • 
F. Duwaine Townsen, /Chairman Robert1 X. Condie, ^ Director 
n 
John T. Gordy, Director-
